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Abstract 
Glycation is a non-enzymatic reaction with reactants including a 
reducing sugar and a free amino containing molecule such as protein, 
amino acids, DNA, RNA and lipids. In the initial phase of glycation, the 
carbonyl group of the reducing carbohydrate condenses with the free amino 
groups on the target biomolecule to form reversible glycosylamines, which 
are then converted to more stable Amadori products. Once formed, these 
Amadori products can with time undergo dehydration, cyclization, oxidation, 
and rearrangement to form a polymorphic group of compounds collectively 
referred to as Advanced Glycation Endproducts (AGEs). The accumulation 
of AGEs in vivo has been implicated as a major pathogenic process in 
diabetic complications including diabetic cataract formation, retinopathy and 
neurological diseases, as well as other health disorders, such as 
Alzheimer’s disease (AD).  
Chapter one reviewed the chemistry of glycation and the formation of 
AGEs in a mechanical perspective. The role of AGEs in the pathogenesis of 
diabetic nephropathy, diabetic neuropathy, diabetic retinopathy and 
Alzheimer’s disease were considered. Here we also reviewed the potential 
inhibitors against glycation published to date, focusing on some novel 
potential AGE inhibitors such as zinc and gold nanoparticles. 
The purpose of the study described in chapter two was to investigate 
the susceptibility of the amine groups of melamine to glycation by milk 
 
 
sugars and sugar metabolites. Dairy products adulterated with melamine 
have been recently blamed for the death of at least several infants and the 
sickening of countless children in China. The presented study described the 
non-enzymatic glycation of melamine with milk sugar D-galactose and 
several sugar metabolites including methylglyoxal, glyoxal and 
DL-glyceraldehyde. The chemical structures of melamine AGEs were 
characterized by electrospray mass spectrometry. The factors influencing 
the rate and extent of melamine’s glycation were also evaluated.  
The third part of the dissertation described a study on anti-glycation 
effect of gold nanoparticles (GNPs). In this study we showed that certain 
sizes of spherical GNPs exhibit an inhibitory effect on the formation of AGEs 
when Bovine Serum Albumin (BSA) was glycated by D-ribose. A 
combination of UV spectrometry, HPLC and circular dichroism showed that 
only GNPs with size ranging from 2nm to 20nm inhibited the formation of 
BSA AGEs. The inhibition effect of GNPs was correlated to the overall 
surface area of nanoparticles in the solution. GNPs with higher surface 
areas were found to be better inhibitors of glycation, whereas those with low 
surface areas were less effective inhibitors. The inhibitory effect of GNPs on 
non-enzymatic glycation reactions may be due to the covalent bonding 
between gold atoms on the surface of GNP and ε amino groups of L-lysine 
residue on protein.  
In chapter four, we evaluated the effect of UVC radiation on glycation of 
 
 
Human Serum Albumin (HSA). In this study, we found that exposure to UVC 
radiation accelerated the glycation level of HSA and promoted the formation 
of AGEs, which may be stimulated by the generation of ROS by UVC 
radiation. A combination of several analytical methods including UV 
spectrometry, HPLC, and MALDI-TOF were used to evaluate the glycation 
level of HSA at 37 °C under neutral pH in the presence of D-glucose in vitro. 
This study warrants further investigation as there have been few reports on 
the correlation between the UVC radiation of proteins and their enhanced 
glycation by a reducing sugar.   
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Preface 
This dissertation presents one review article and two scientific projects. 
All three manuscripts focus on the chemistry of glycation, a non-enzymatic 
reaction which plays an important role in the pathogenesis of diabetic 
complications including atherosclerosis, renal failure and cardiovascular 
disease. Chapter one reviews the mechanism and biological effects of 
glycation. Chapter two describes the glycation reaction of melamine with 
sugars found in milk and their metabolic products. Chapter three presents 
the study of gold nanoparticle’s anti-glycation property when bovine serum 
albumin is glycated by D-ribose. Chapter four presents the study on 
enhancement effect of UVC radiation on the glycation level of HSA. 
The dissertation is written in manuscript format. Manuscript two has 
been accepted by Bioorganic Chemistry in September 2012 and is 
expected to be published in the journal’s latest issue. Manuscript one was 
prepared according to the format guidelines of Biochimica Biophysica Acta 
while manuscript three and manuscript four were prepared according to the 
format guidelines of Analytical Biochemistry. 
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Abstract 
Glycation is a non-enzymatic reaction between reducing sugars and 
amino groups in proteins, nucleic acids and lipids. The final products of this 
reaction are a polymorphic group of compounds collectively referred to as 
Advanced Glycation Endproducts (AGEs). The gradual built-up of AGEs in 
body tissues plays an important role in the pathogenesis of diabetic 
complications including atherosclerosis, renal failure and cardiovascular 
disease. Recent studies suggest that AGEs selectively bound to AGE 
receptors found in several cell types, many of which are affected by 
diabetes. The interaction of AGEs to these receptors triggers the release of 
pro-inflammatory molecules and free radicals, inducing oxidative cellular 
dysfunction. The intracellular uptake of AGEs also alters cell signaling and 
gene expression that contribute towards the pathology of diabetic 
complications. This article reviews the chemistry of glycation and the 
formation of AGEs in a mechanical perspective. The role of AGEs in the 
pathogenesis of diabetic nephropathy, diabetic neuropathy, diabetic 
retinopathy and Alzheimer’s disease are considered. Here we also review 
the potential inhibitors against glycation published to date, focusing on 
some novel potential AGE inhibitors such as zinc and gold nanoparticles.  
 
Key words: glycation; AGEs; diabetes; ROS 
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1.1 Introduction 
The Non-enzymatic reaction between the carbonyl group of a reducing 
sugar and the amino containing molecule such as protein, peptide or amino 
acid was first studied under defined conditions by Louis Camille Maillard in 
1912. Ever since its description in early 1900s, the Maillard reaction has 
continued to be a topic of research interest. For researchers in nutrition 
science, harnessing the Maillard reaction has allowed for controlling food 
flavor, food aroma, food coloring, and food texture. In addition to its benefits, 
the Maillard reaction occurring during food processing also results in the 
loss of protein quality and the formation of harmful compounds with 
mutagenic, carcinogenic and genotoxic properties (1-3). 
During the 1970s and 1980s, researchers in clinical medicine realized 
that this process also occurs slowly in vivo. Subsequently, Maillard reaction 
in vivo was termed glycation, distinguished from enzymatic glycosylation. 
The final products of this reaction are a polymorphic group of compounds 
collectively referred to as Advanced Glycation Endproducts (AGEs). The 
gradual built-up of AGEs in body tissues plays an important role in the 
pathogenesis of diabetic complications including atherosclerosis, renal 
failure and cardiovascular disease. Glycation is also found to be related to 
other health disorders such as Alzheimer Diseases (AD) and normal aging 
(4-6). 
Intracellular hyperglycemia can induce the formation of glucose-derived 
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dicarbonyl molecules such as glyoxal, methylglyoxal and 3-deoxyglucosone. 
These intracellular dicarbonyls, also called AGE precursors, are much more 
reactive comparing to D-glucose due to their lack of cyclic structure and 
comparatively smaller size. AGE precursors glycate with amino groups of 
both intracellular and extracellular proteins at a much faster rate than 
D-glucose, leading the accumulation of AGEs. These AGEs specifically 
binds to a certain groups of cell surface receptors (RAGEs), inducing 
receptor-mediated production of reactive oxygen species (ROS), finally 
resulting in oxidative cellular dysfunction (3, 7). AGEs such as glyoxal lysine 
dimer (GOLD) and methylglyoxal lysine dimer (MOLD) are responsible for 
protein crosslinking on longest-lived extracellular proteins such as collagen 
and elastin. Such proteins provide strength and flexibility to tissues, and do 
not get recycle very often. Glycation and crosslinking gradually change the 
property and function of these proteins, reduce their flexibility and elasticity, 
and increase their stiffness as well. This process has been implicated as 
strong contributors to many progressive diseases of aging, including 
vascular diseases, stiffness of joints, arthritis and kidney failure (4-6). 
Both synthetic compounds and natural products have been found to be 
inhibitors against the formation of AGEs. These glycation inhibitors are 
proposed to block the formation of intermediate Amadori products, or break 
the crosslinking of proteins. Their classification and corresponding inhibition 
mechanism will be discussed later in this article. 
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1.2 The chemistry of glycation 
Glycation is a non-enzymatic browning reaction that involves a series of 
steps with the reactants typically including a reducing sugar and a free 
amino containing molecule. The progress of the reaction includes three 
distinguishable phases: the initial stage, the intermediate stage and the late 
stage. In the initial phase of glycation, the carbonyl group of a reducing 
carbohydrate condenses with the free amino group on a protein or other 
amino containing molecule to form reversible glycosylamine, which is then 
converted to more stable Amadori products. Under appropriate condition, 
these Amadori products could degrade to more reactive dicarbonyls such as 
methylglyoxal, glyoxal and glyceraldehyde. These intermediates are 
responsible for most of the AGE formation due to their high reactivity. In the 
late stage of glycation, the Amadori product itself could with time undergo 
dehydration, cyclization, oxidation, and rearrangement to form AGEs. 
Meanwhile, the AGE precursors formed from the intermediate stage of 
glycation such as methylglyoxal will in turn interact with protein or other 
amino containing molecules to produce AGEs at a much higher reaction 
rate comparing to reducing sugars. 
1.2.1. Initial stage: formation of Amadori products 
In the initial phase of glycation, the nitrogen atom of a terminal 𝛼-amino 
group or of the ε-amino group on lysine or arginine residue covalently 
condenses with the carbonyl group of a reducing sugar by nucleophilic 
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attack. The product of this reaction contains an unstable aldimine structure 
named Schiff base. The formation of Schiff base is reversible due to the 
unstable property of aldimine functional group. Schiff base intermediate can 
then undergo Amadori rearrangement to produce a relatively stable 
ketosamine structure, referred to as Amadori product (See figure 1). 
Formation of Amadori product from Schiff base is much faster than the 
reversed reaction so Amadori adducts tend to accumulation on proteins. 
This process is thought to be facilitated by localized acid-base catalysis if 
there is a histidine or lysine side chain about 5 Å from the target amino 
residue (8).  
1.2.2. Intermediate stage: formation of AGE precursors 
AGE precursors are formed in vivo via two major pathways: 1) the 
fragmentation of Amadori products or Schiff base, and 2) the metabolic 
degradation of D-glucose. The physiologically relevant D-glucose is one of 
the least reactive reducing sugars in protein glycation (9). Under 
physiological condition, over 90% of D-glucose is in cyclic confirmation 
which cannot be a target of the nucleophilic attack by a primary amino group. 
However, other sugars and dicarbonyl compounds, many of which are found 
intracellular such as glyoxal (Gly), 3-deoxyglucosone (3-DG) and 
methylglyoxal (MG) participate in glycation at a proportionally faster rate (10, 
11). Gly is formed from several reactions such as the oxidative 
fragmentation of Schiff base via the Namiki pathway (12, 13), glucose 
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auto-oxidation catalyzed by metal (Wolff pathway) or lipid peroxidation via 
the Acetol pathway (14, 15). 3-DG is produced from non-oxidative 
fragmentation and hydrolysis of Amadori product. 3-DG also forms from 
fructose-3-phosphate, an intermediate of the Polyol pathway in which 
glucose is reduced to sorbitol by aldose reductase. Further degradation of 
3-DG generates methylglyoxal and glyceraldehyde (GA) by retro-aldol 
condensation (16, 17). Methylglyoxal is found to be one of the most reactive 
glycation agents, and could react with different amino acids including lysine 
and arginine to generate dicarbonyl-derived AGEs. MG could also alter the 
secondary structure of a protein, resulting in the loss of its function (18, 19). 
A summary of the sources of these reactive carbonyl species are shown in 
figure 2. 
The increase in the concentration of reactive carbonyl compounds from 
glycoxidation, lipoxidation or the degradation of Schiff base/Amadori 
adducts will lead to carbonyl stress (20, 21), a situation that aggravates the 
modification of proteins and prompts the formation of AGEs. Figure 3 is a list 
of chemical structures of currently well-defined AGE dicarbonyl precursors 
and their interactions with glycated proteins. 
1.2.3. Late stage: formation of AGEs 
AGEs are a group of heterogeneous compounds including fluorescent 
crosslinking structures such as pentosidine, non-fluorescent crosslinking 
substances such as glyoxal lysine dimer (GOLD) or methylglyoxal lysine 
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dimer (MOLD), and non-fluorescent, non-crosslinking compounds such as 
Nε-carboxymethyl lysine (CML). AGEs are produced both in vitro and in vivo 
via several pathways, including direct degradation of Amadori products or 
Schiff base, protein modification by dicarbonyl compounds and reactions 
between Amadori products and AGE precursors.  
One of the major consequences of protein being modified by active 
dicarbonyl glycation agents is the formation of protein cross-links, a 
situation that is related to several diabetic complications. Reactions of 
dicarbonyl compounds with lysine and arginine residue or with Amadori 
intermediate are involved in the formation of many AGE crosslinking 
structures which exhibit fluorescence absorbance (Figure 4). Among these 
compounds, pentosidine from the glycation of ribose has been determined 
in many tissues such as lens proteins and skin collagens (22). Pentosidine 
can also be formed from several more reactive carbohydrate intermediates 
including 3-DG and fructose. It has been recently proposed as an index for 
evaluating tissue damage under glycation condition (23). 
Although fluorescent crosslinking AGEs are important biomarkers of 
hyperglycemia condition due to their easy of detection, these structures are 
account for only a small portion of protein crosslinks which is about 1% in 
physiological condition (24). On the other hand, non-fluorescent crosslinking 
AGEs are the major contribution to in vivo protein-protein crosslinks. A 
group of most well defined crosslinking structures are imidazolium 
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crosslinks including glyoxal-derived AGE glyoxal-lysine dimer (GOLD) and 
methylglyoxal-derived AGE methylglyoxal-lysine dimer (MOLD) (25, 26). 
Both of these structures are found in human lens protein and human serum. 
(27-29). Glyoxal and methylglyoxal could irreversibly modify the ε-amino 
group of lysine residues in protein under physiological condition to form 
these imidazolium compounds which are responsible for protein 
crosslinking.  
The third class of AGEs is non-fluorescent, non-crosslinking structures, 
which act as biological receptor ligands to initiate cellular signaling and 
induce tissue oxidation stress. These compounds could also perform as 
precursor of protein crosslinks. The chemical structures of some of the most 
important and well-studied non-crosslinking AGEs including pyrraline, 
1-carboxyalkyl lysine and imidazolone A and B are shown in figure 5.  
3-DG rapidly reacts with lysine residues of a protein to form pyrraline. 
Though pyrraline itself is not a crosslink structure, it may cause crosslinks 
between proteins when its aldehyde group forms a Schiff base with another 
amino group, resulting in lysine-lysine or lysine-arginine crosslinking in vivo. 
Imidazolone is derived from reaction of dicarbonyl compounds with the 
guanidino group of an arginine residue.  
AGEs such as Nε-carboxymethyl lysine (CML) and Nε-carboxymethyl 
lysine (CEL) with a carboxyalkyl group attached to the ε-amino group of an 
amino acid are found in vivo. CML is known as one of the most well 
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characterized AGEs which is used as a biomarker for long-term protein 
damage in diabetes and oxidative tissue abnormality. CML can be produced 
through different pathways including glycation and oxidation reactions (22, 
30, 31), resulting in its wide distribution in a variety of tissues such as serum, 
skin collagen and kidney. 
CML is produced through four major pathways shown in figure 6: 1) 
oxidative cleavage of Amadori product 2) Schiff base degradation through 
Namiki pathway (32); 3) oxidation of ascorbic acid (33) and 4) autoxidation 
glycosylation with lysine and glyoxal (32). The oxidative degradation of 
Amadori adducts is thought as the major source of CML formation (25, 34). 
Under physiological condition, CML is found to be produced mainly from 
fructoselysine, an Amadori intermediate derived from fructose and lysine. 
The Schiff base can undergo degradation via Namiki pathway to form active 
carbonyl compounds such as glyoxal and its corresponding imine analog, 
which are responsible for the formation of CML. The other CML precursor 
formed via Namiki pathway is aminoaldehyde. Aminoaldehyde could oxidize 
to CML by any of the oxygen reactive species present in the glycation 
system, or by oxygen under metal catalysis. Other sources of CML 
formation include the oxidation of ascorbic acid derived from glucose and 
direct condensation of glyoxal with the ε-amino group of lysine residues in 
proteins. 
1.3. Biological effects of glycation 
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   Non-enzymatic glycation has been thought to play an important role in 
the pathogenesis of diabetic complications including cataract formation, 
renal failure and cardiovascular disease. Glycation is also approved to be 
related to other health disorders such as Alzheimer’s disease (AD), 
atherosclerosis and normal aging. Most of the effects of glycation which 
lead to chronic complications are due to AGE accumulation on long-lived 
proteins such as collagen and lens crystallins. In the meantime, glycation 
can induce the formation of reactive oxidation species (ROS), causing 
oxidation stress and tissue damage (35, 36). 
1.3.1 Physiological defense system against glycation 
There are several defense systems occurring physiologically against 
the deleterious effects of AGE, including enzymes such as aldose reductase， 
which inhibit the formation of AGE precursors or antioxidants such as 
glutathione which reduce the production of reactive oxidative species. 
Aldose reductase is a NADPH-dependent enzyme that catalyzes the 
degradation of dicarbonyl AGE intermediates including MG and 3-DG 
(37-39). Most recently, fructoselysine, an Amadori intermediate derived from 
fructose and lysine, was found to be phosphorylated by human 
fructosamine-3-kinase (FN3K) and spontaneously degradation afterwards 
(40). The glyoxalase system catalyzes the conversion of methylglyoxal to 
D-lactic acid by glyoxalase I and glyoxalase II. This system is present in the 
cytosol and mitochondria of cells and has a wide distribution in living 
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organisms (41, 42). Another natural common defense mechanism is 
glutathione (GSH) system. GSH is an antioxidant, preventing oxidative 
damage to tissues caused by reactive oxidative species such as peroxides 
and free radicals, whose formations are prompted by glycation. GSH also 
facilitated the rearrangement of methylglyoxal to D-lactate in the glyoxalase 
pathway (43). 
1.3.2 AGE mediated cell-signaling  
Intracellular accumulation of AGEs damages target cells through 
receptor-mediated pathway, in which the glycated plasma proteins bind to 
AGE receptors on the cell surface, inducing cell signaling and oxidation 
stress (see figure 7). Several AGE binding proteins have been identified 
such as RAGE, the AGE receptor complex (AGE-RG) and macrophage 
scavenger receptor (44-46), many of which play a critical part in the 
pathology associated with AGE related complications.  
In endothelial cell system, plasma proteins modified by AGEs act as 
ligands to AGE receptors found on the surface of the cell. This process 
activates intracellular transducers and leads to the changes in gene 
expression. A rise in the expression of pro-inflammatory and 
pro-coagulatory molecules was found in endothelial cell when it was 
exposed to high glucose (47-50). RAGE is a member of the immunoglobulin 
receptor family. Pro-inflammatory NF-κB pathway is thought to be one of the 
major targets of RAGE. The activation of the pathway is related to several 
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inflammatory diseases in diabetes. In addition, NF-κB in turn elevates 
RAGE expression, establishing a positive feed-back cycle. In summary, the 
intracellular accumulation of AGE results in the increase of RAGE ligands, 
activating NF-κB pathway and lead to chronic inflammation.  
Additionally, AGE receptors are found on the surface of macrophage 
and mesangial cell. Binding of AGE ligands to the receptor induces the 
formation of reactive oxygen species (ROS) including peroxyl, superoxide 
anions, hydroxyl radicals and hydrogen peroxides (structures seen in figure 
8). As discussed previously in this article, the abnormal excess of ROS 
under hyperglycemia conditions originate from several mechanisms 
including the degradation of glycation intermediates, the by-production of 
carbonyl AGE precursors, and cellular oxidant stress triggered by RAGE. 
The abnormal accumulation of ROS caused by hyperglycemia is known to 
mediate the progression of several chronic complications due to the 
impaired antioxidant defense system. Such situation is defined as oxidative 
stress. Pathways for the generation of ROS which lead to oxidative stress 
are summarized in figure 9. The rise in the oxidant level in a living organism 
can cause damage to various cell components and triggers the activation of 
certain cell signaling pathways, resulting in pathological changes in gene 
expression. 
1.3.3 AGE induced protein dysfunction 
Several intracellular proteins modified by glycation are found to have 
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altered activities and stabilities. One example is serum albumin, the most 
abundant protein in blood plasma which exhibits a broad range of 
physiological functions such as catalytic activities. Serum albumin can 
catalyze the hydrolysis of esters, showing an esterase-like activity. However, 
its enzymatic activity is impaired drastically when the protein is glycated by 
methylglyoxal. Since a lysine residue of the protein has been suggested as 
the catalytic center, the loss of the protein’s esterase activity is thought to be 
related to the modification of this lysine residue by glycation agents (51). 
Another example of dysfunctional AGE modified protein is proteases, a 
class of enzymes which degrade polypeptides. The catalyze sites of this 
enzymes include cysteine and histidine, both of which can be glycated by 
methylglyoxal, resulting in the loss of enzymes’ activity (52). 
AGE formation does not only alter the activity of intracellular proteins, 
but affect the functional properties of important molecules on extracellular 
matrix such as various types of collagens. Collagen is the main components 
of connective tissue, responsible for skin elasticity, blood vessel strength 
and tissue regeneration. This type of proteins has a comparatively long 
biological half-life and is exposed to extracellular glucose whose level is 
considerably higher than that inside the cell. Collagen can react with other 
collagen molecules through protein crosslinking by some typical AGE 
structures including methylglyoxal lysine dimer (MOLD) and glyoxal lysine 
dimer (GOLD). Such crosslinking structures can be gradually built up during 
15 
 
normal aging and are accumulated much faster under hyperglycemia 
condition. As a result, the formation of MOLD and GOLD plays a critical role 
in the pathologenesis of vascular stiffening and atherosclerotic lesions (17).  
1.4 AGEs and diseases  
The accumulation of AGEs has been implicated as strong contributors 
to many progressive diseases including diabetic complications, aging and 
Alzheimer’s disease. AGEs play a role in the pathogenesis of such health 
disorders through three major mechanisms: 1) AGE modified plasma 
proteins could bind to AGE receptors on the surface of the cell, activate cell 
signaling and lead to the production of ROS and inflammatory factors; 2) 
intracellular proteins, specifically catalytic proteins, could lose their function 
and stability if the activate site is glycated by AGE precursors; 3) proteins on 
the extracellular matrix such as collagen could crosslink with other matrix 
components, leading to the loss in their function. 
1.4.1 AGEs and diabetic complications 
1.4.1.1 Diabetic nephropathy 
Diabetic kidney disease is one of the major microvascular 
complications of diabetes. The hyperglycemia related mechanisms of 
diabetic nephropathy can be explained in three pathways. First, by binding 
to signaling cell surface receptors, AGEs can activate protein kinase C 
(PKC) which plays a center role in the pathogenesis of diabetic nephropathy. 
Second, binding of AGEs to their receptors can increase the expression of 
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several transcription factors and enhance the formation of ROS. Third, the 
intracellular AGEs also initiate cell signaling events which alter the 
expression of extracellular matrix proteins including type I and type IV 
collagens. Meanwhile, AGEs can form crosslinking structures with collagens, 
causing altered cell adhesiveness and capillary permeability.  
PKC is an intracellular signaling kinase which can be activated by the 
binding of AGEs with RAGE. The activation of PKC will lead to endothelial 
dysfunction resulting in altered blood flow and capillary permeability. PKC 
can also induce the generation of pro-inflammatory factors such as NF-κB 
and lead to local tissue inflammatory (53, 54). Hyperglycemia condition 
promotes the generation of ROS during or after the formation of AGEs. 
There is considerate in vitro study suggesting the involvement of ROS in the 
pathogenesis of renal injury. The generation of ROS is coupling with the 
biological alteration of tubular cells with loss of epithelial cell adhesion (55). 
Moreover, the balance of nitroso-redox can be disturbed by the formation of 
ROS when the radicals inactive relaxing nitric oxide and cause hypertension. 
Besides the activation of PKC and the up-modulation of ROS, the 
accumulation of AGEs causes the increased synthesis of extracellular 
matrix and decreased expression of its degrading enzymes, leading to the 
polymerization and expansion of extracellular matrix proteins (56-58). 
1.4.1.2 Diabetic neuropathy 
The symptoms of diabetic neuropathy often develop slowly over years, 
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including the loss of sensation, nausea, deep pain in legs and feet. The 
pathology can be characterized by progressive nerve fiber lose caused by 
long-term high blood sugar level in diabetes. The precise mechanisms 
underlying diabetic neuropathy is unclear, however most recent study 
suggests that the loss in nerve fiber can be caused by multiple pathways 
including the enhanced polyol pathway under hyperglycemia condition, the 
increased protein modification by AGEs and the up-regulated oxidation 
stress.     
In polyol pathway, glucose is degraded to sorbitol by aldose reductase. 
This process can be up-regulated under hyperglycemia condition, causing 
increased consumption of NADPH and reduced formation of glutathione. 
The impaired synthesis of glutathione will then cause vascular insufficiency 
and degeneration of nerve fibers (59). The activation of polyol pathway also 
suppresses the activity of protein kinase C, and eventually elicits reduced 
nerve blood flow and decreased nerve conduction (60). Meanwhile, the 
binding of AGEs to their receptors has been found to induce oxidative stress, 
result in over expression of pro-inflammatory genes, and exaggerate 
neurological dysfunction, including altered pain sensation. The AGE-RAGE 
interaction can also activate the formation of extracellular matrix proteins. 
AGEs in terns covalently bond to these proteins to form crosslink structures, 
and lead to the development of vascular abnormalities, such as thickening 
of capillary basement membrane. 
18 
 
1.4.1.3 Diabetic retinopathy 
Many in vitro and in vivo studies showed that AGEs play a significant 
pathogenic part in diabetic retinopathy, when the retinal microvascular 
becomes dysfunctional progressively, resulting in damage to the retina of 
the eye (61). The accumulation of AGEs is proposed to participate in the 
progression of the disease via three pathways. First, the binding of AGEs to 
their receptors induce the formation of vascular basement membrane 
proteins. These proteins are then cross-linked by certain species of AGEs, 
resulting in basement membrane thickening and the breakdown of the inner 
blood-retinal barrier (62, 63). Second, AGEs-RAGE binding inappropriately 
initializes intracellular signaling, cause abnormal expression of transducers 
or growth factors, which result in the failure of endothelial cells. Third, retinal 
vascular endothelia cells show disturbed nitric oxide expression when 
exposed to high concentration of AGEs, which may be a cause of capillary 
closure and retinal ischemia.  
Besides diabetic retinopathy, the cataract formation is another major 
complication developing gradually in diabetes disorder. Under 
hyperglycemia condition, there is an increased production of highly reactive 
dicarbonyl compounds such as methylglyoxal and glyoxal. These molecules 
not only act as AGE precursors but also cause AGE crosslinks and protein 
aggregations on crystallins, leading to the formation of cataract (64-66). 
Other study suggests that oxidation stress, which is upgraded by glycation, 
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can promote the formation of cataract as well.  
1.4.2 AGEs and Alzheimer’s Diseases 
Alzheimer’s disease (AD) is an age-related chronic complication which 
severely affects patients’ memory and behavior in their late life. The causes 
of such disease include early stage triggering events and late stage 
inflammation and neurodegeneration. Several studies suggest that the 
formation of AGEs plays an important role in the pathogenesis of AD.  
The deposition of β-Amyloid (Aβ) in the cerebral cortex is one of the 
major pathological features of AD. Aβ peptides contain 39 to 43 amino acid 
residues and are found overproduced in AD brains. These peptides are 
thought to be one of the most important contributors to neurodegeneration 
(67, 68). Solid evidence revealed that extensive protein crosslinking and the 
increased production of ROS, inflammatory factors and reactive dicarbonyl 
compounds are responsible for AD characteristics including the Aβ deposit 
(69). Meanwhile, all the above mentioned chemical processes are related to 
glycation and AGEs, whose formation is found to be accelerated in AD.  
It has been suggested that the accumulation of AGEs is involved in the 
pathogenesis of AD through two major mechanisms including AGE-RAGE 
interaction and protein-Aβ crosslinking. As described in the previous chapter, 
AGE modified proteins can interact with cell surface receptors such as 
RAGE, and trigger a serial of cellular signaling pathways. Besides AGEs, Aβ 
is found to be another ligand of RAGE. The interactions of AGEs and Aβ 
20 
 
with RAGE elicit the production of ROS and pro-inflammatory factors. The 
generation of these molecules will then cause oxidative stress and 
inflammatory, subsequently leading to neuronal dysfunction. The 
accumulation of AGEs is also responsible for protein-Aβ crosslinks, a major 
cause to neurodegeneration in AD. Such binding down-regulates the 
expression of genes involved in Aβ clearance, resulting in Aβ accumulation. 
1.4.3 AGEs and aging  
Hyperglycemia is shown to be correlated to several age-related 
diseases and the controlling of such condition prolonged life span in 
experimental animals. Hyperglycemia induces the formation of AGEs when 
protein is glycated by reducing sugars or active dicarbonyl compounds. 
AGEs up-regulate oxidative stress and inflammation, cause crosslinks on 
long lived protein such as extracellular matrix and vascular basement 
membrane, and reduce the clearance of harmful protein aggregations. Thus 
AGEs play a significant role in the pathogenesis of several diseases across 
different organ systems, many of which are age-related. AGEs interact with 
their receptors and trigger the induction of ROS and pre-inflammatory 
factors. AGEs and AGE receptors are found in different cell types including 
smooth muscle cells, endothelium and mono nuclear cells. Such wide 
distribution of these compounds causes the chronic damage to virtually 
every tissue in the body. Meanwhile, AGEs elicit protein cross-links and 
affect most on tissues composed with long-lived proteins such as skin, 
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skeletal muscle, heart, arteries and lens. AGE-mediated protein crosslinking 
in connective tissues causes the loss in their elasticity and flexibility, 
resulting in skin aging, hypertension and cataract formation.  
1.5 Inhibitors against AGE formation 
Since non-enzymatic glycation of proteins is a major contributor to the 
pathology of diabetes and other diseases including AD, the inhibitors to 
prevent the formation of AGEs have been extensively investigated and a 
number of potential AGE inhibitors have been proposed over years. A 
schematic of in vivo glycation reactions is shown in figure 10. On this 
scheme are also common targets for AGE inhibition which are labeled by 
circled letters from A to F. Type A and type B inhibitors prevent the formation 
of Amadori product at the initial stage of glycation by competing with 
glycation agents (type A) or reacting with reducing sugars (type B) (70-72). 
Other types of inhibitors (type C1 and C2) disturb glycation mechanisms 
such as Wolff pathway and Namiki pathway, enhance antioxidant activity, 
and reduce the production of dicarbonyl AGE precursors. Type D drugs 
interact with reactive dicarbonyl compounds such as methylglyoxal and 
glyoxal, preventing their binding to protein (73, 74). Comparing to class D, 
class E compounds directly act on Amadori adducts, and trap it from further 
modification (75). Instead of preventing AGE formation, drugs in F group 
reduce AGE toxicity by breaking protein-AGE cross-linking. There are also 
numbers of novel AGE inhibitors such as zinc and nanoparticles, whose 
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inhibition mechanisms are still under investigation.  
1.5.1. Carbonyl compounds scavengers 
The first and most well-known synthetic glycation inhibitor is 
aminoguanidine (AG) (76), whose structure can be found in figure 11. 
Aminoguanidine prevents the formation of AGEs by reacting with reactive 
dicarbonyl compounds such as methylglyoxal and glyoxal, hindering the late 
stage of glycation. Several in vivo studies demonstrated that AG retarded 
the development of several diabetes related complications including renal 
failure and cataract formation (77). Unfortunately, AG showed considerable 
toxicity to human body during clinical trial, thus structural modification on the 
compound is required to reduce its toxicity. Pyridoxamine (PM), one of the 
vitamin B complexes, is another potent carbonyl scavenger which showed 
better inhibitory effect on reducing the glycation level in bovine serum 
albumin model (78). PM inhibits the formation of AGEs not only by trapping 
the reactive dicarbonyl AGE precursors, but by blocking the oxidative 
degradation of the Amadori intermediates as well, preventing it from further 
modification by reducing sugars (79).  
1.5.2 AGE breakers 
Cell tissue constantly exposed to AGEs tent to lose its function due to 
protein crosslinking. Recently, a few AGE breakers have been discovered to 
combat deleterious protein cross-links. Their structures are shown in figure 
12. This class of anti-glycation agents provides a potential new therapeutic 
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approach especially for diabetic cardiovascular disease. Patients who 
received alagebrium chloride (ALT-711), one of the most well studied AGE 
breakers, showed significant reduction in arterial pulse pressure (80). 
Another prototypic protein cross-link breaker is N-phenacylthiazolium 
bromide (PTB). PTB reacts with AGE-induced protein aggregates and 
covalently cleaves protein crosslinking structures (81). 
1.5.3 Dietary antioxidant 
A dietary antioxidant is considered to be relatively safe for human 
consumption comparing to above mentioned synthetic compounds. The 
accumulation of AGEs induces the formation of ROS, leading to cell 
dysfunction and tissue damage. Dietary antioxidants are substances found 
in food that decrease the damage of ROS, and restore physiological 
function in humans. Vitamin C and vitamin E, for instance, both prevented 
the formation of AGEs in experimental models. Treatment of diabetic rats 
with these antioxidants resulted in a reduced plasma lipid peroxidation level. 
The study also showed that vitamin E has a potent to restore nerve system 
by reversing nerve conduction velocity deficits (82).  
1.5.4 Novel AGE inhibitors 
Besides synthetic anti-glycation agents and traditional dietary 
substances which reduce the damage of ROS, some novel AGE inhibitors 
have also been proposed recently, including zinc and gold nanoparticles 
(GNP). In a recent in vitro study, human serum albumin treated with different 
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concentrations of zinc showed lower glycation level comparing to control 
experiment, suggesting that zinc inhibited the formation of AGEs. In this 
study, a combination of analytical methods was used to evaluate the level of 
protein glycation. Moreover, the treatment of zinc not only reduced the 
formation of glycation products, but also retained protein’s secondary 
structure, an observation which was confirmed by circular dichroism. Zinc 
was proposed to inhibit glycation by binding to the reactive sites on the 
protein and preventing sugar’s non-enzymatic condensation with these sites 
(83). GNP is another substance which showed anti-glycation activity as well 
as satisfying bio compatibility. In one study, spherical gold nanoparticles 
(GNPs) with a diameter of 2 nm showed an inhibition effect on the formation 
of AGEs when human serum albumin was glycated with DL-glyceraldehyde. 
The inhibitory effect of GNPs on non-enzymatic glycation reactions may be 
due to the covalent bonding between gold atoms on the surface of GNP and 
ε amino groups of L-lysine residue on protein. As GNP is highly 
biocompatible and water soluble, an insight of its anti-glycation effect and its 
inhibition mechanism on the formation of AGEs might lead to a novel 
therapeutic application of GNP on reducing AGE related complications (84). 
 
1.6. Conclusion 
In conclusion, glycation is a non-enzymatic reaction with reactants 
including a reducing sugar and a free amino containing molecule such as 
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protein, amino acids, DNA, RNA and lipids. In the initial phase of glycation, 
the carbonyl group of the reducing carbohydrate condenses with the free 
amino groups on the target biomolecule to form reversible glycosylamines, 
which are then converted to more stable Amadori products. Once formed, 
these Amadori products can with time undergo dehydration, cyclization, 
oxidation, and rearrangement to form a polymorphic group of compounds 
collectively referred to as Advanced Glycation Endproducts (AGEs). The 
accumulation of AGEs in vivo has been implicated as a major pathogenic 
process in diabetic complications including diabetic cataract formation, 
retinopathy and neurological diseases, as well as other health disorders, 
such as aging and Alzheimer’s disease (AD).  
AGEs play a role in the pathogenesis of such health disorders through 
different yet complicated cellular mechanisms including ligand induced cell 
signaling which causes oxidative stress and inflammation; protein 
dysfunction due to modification on the active site by glycation; and protein 
crosslink which leads to its denaturation. The inhibitors to prevent the 
formation of AGEs have been extensively investigated based on these 
pathways. The most promising glycation inhibitors include amino-guanidine 
and pyridoxamine which trap the active dicarbonyl molecules and prevent 
the formation of AGEs. Some novel anti-glycation substances such as zinc 
and gold nanoparticles have also been proposed recently. 
 
26 
 
Reference: 
1. Yaylayan, V.A.; Machiels, D.; Istasse, L.J. Agric. Food Chem., 2003, 51, 
3358. 
2. Monti, S.M.; Ritieni, A.; Sacchi, R.; Skog, K.; Borgen, E.; Fogliano, V. J. 
Agric. Food Chem., 2001, 49, 3969. 
3. Persson, E.; Graziani, G.; Ferracane, R.; Fogliano, V.; Skog, K. Food 
Chem. Toxicol., 2003, 41, 1587. 
4. Furth, A.J. Br. J Biomed. Sci., 1997, 54, 192. 
5. Ulrich, P.; Cerami, A. Recent Prog. Horm. Res., 2001, 56, 1. 
6. Thornalley, P.J. Int. Rev. Neurobiol., 2002, 50, 37. 
7. Kato, T.; Harashima, T.; Moriya, N.; Kikugawa, K.; Hiramoto, K. 
Carcinogenesis, 1996, 17, 2469. 
8. Acosta, J.; Hettinga, J.; Fluckiger, R.; Krumrei, N.; Goldfine, A.; Angarita, 
L.; Halperin, J. Proc. Nat. Acad. Sci. U.S.A. 2000, 91, 5450. 
9. Bunn, H.F.; Gabbay, K.H.; Gallop, P.M. Science, 1978, 200, 21. 
10. Li, Y.; Cohenford, M.A.; Dutta, U.; Dain, J.A. Anal. Bioanal. Chem., 2008, 
390, 679. 
11. Li, Y.; Dutta, U.; Cohenford, M.A.; Dain, J.A. Bioorganic Chemistry, 2007, 
35, 417. 
12. Glomb, M.A.; Monnier, V.M. J. Biol. Chem., 1995, 276, 10017. 
13. Dyer, D.G.; Dunn, J.A.; Thorpe, S.R.; Bailie, K.E.; Lyons, T.J.; McCance, 
D.R.; Baynes, J.W. J. Clin. Invest., 1993, 91 , 2463. 
27 
 
14. Wolff, S.P.; Dean, R.T. Biochem. J., 1987, 245, 243. 
15. Wolff, S.P.; Jiang, Z.Y.; Hunt, J.V. Free Radical Biol. Med., 1991, 10, 339. 
16. Martins, S.I.; Marcelis, A.T.; Boekel, M.A. Carbohydr. Res., 2003, 338, 
1651. 
17. Thornalley, P.J.; Langborg, A.; Minhas, H.S. Biochem. J., 1999, 344, 
109. 
18. Shinohara, M.; Thornalley, P.J.; Giardino, I.; Beisswenger, P.; Thorpe, 
S.R.; Onorato J.; Brownlee M. J. Clin. Invest., 1998, 101, 1142. 
19. Meade, S.J.; Miller A.G.; Gerrard, J.A. Bioorg. Med. Chem., 2003, 11, 
853. 
20. Miyata, T.; Ypersele de Strihou, C.; Kurokawa K.; Baynes, J.W. Kidney 
Int., 1999, 55, 389. 
21. Miyata, T. Bull. Mem. Acad. R. Med. Belg., 2002, 157, 189. 
22. Sell, D.R.; Monnier, V.M. J. Clin. Invest., 1990, 85, 380. 
23. Sell, D.R.; Nagaraj, R.H.; Grandhee, S.K.; Odetti, P.; Lapolla, A.; Fogarty 
J.; Monnier, V.M. Diabetes Metab. Rev., 1991, 7, 239. 
24. Dyer, D.G.; Blackledge, J.A.; Thorpe S.R.; Baynes, J.W. J. Biol. Chem., 
1991, 266, 11654. 
25. Glomb, M.A.; Monnier, V.M. J. Biol. Chem., 1995, 276, 10017. 
26. Wolff, S.P.; Dean, R.T. Biochem. J., 1987, 245, 243. 
27. Chellan, P.; Nagaraj, R.H. Arch. Biochem. Biophys., 1999, 368, 98. 
28. Brinkmann, E.; Degenhardt, T.P.; Thorpe, S.R.; Baynes, J.W. J. Biol. 
28 
 
Chem. , 1998, 273, 18714. 
29. Nagaraj, R.H.; Shipanova, I.N.; Faust, F.M.  J. Biol. Chem., 1996, 271, 
19338. 
30. Dunn, J.A.; McCance, D.R.; Thorpe, S.R.; Lyons, T.J.; Baynes, J.W. 
Biochemistry, 1991, 30, 1205. 
31. Vrdoljak, A.; Trescec, A.; Benko, B.; Hecimovic, D.; Simic, M.  Clin. 
Chim. Acta, 2004, 345, 105 
32. Wells-Knecht, K.J.; Zyzak, D.V.; Litchfield, J.E.; Thorpe, S.R.; Baynes, 
J.W. Biochemistry, 1995, 34, 3702. 
33. Dunn, J.A.; Ahmed, M.U.; Murtiashaw, M.H.; Richardson, J.M.; Walla, 
M.D.; Thorpe, S.R.; Baynes, J.W. Biochemistry, 1990, 29, 10964. 
34. Ahmed, M.U.; Thorpe, S.R.; Baynes, J.W. J. Biol. Chem., 1986, 261, 
4889. 
35. Baynes, J.W.; Thorpe, S.R. Diabetes, 1999, 48, 1. 
36. Miyata, T.; Ishikawa, N.; Ypersele de Strihou, C. Clin. Chem. Lab. Med., 
2003, 41, 1150. 
37. Boel, E.; Selmer, J.; Flodgaard, H.J.; Jensen, T. J. Diabetes Complicat., 
1995, 9, 104. 
38. Suzuki, K.; Koh, Y.H.; Mizuno, H.; Hamaoka, R.; Taniguchi, N. J. 
Biochem., 1998, 123, 353. 
39. Vander Jagt D.L.; Hassebrook R.K.; Hunsaker, L.A.; Brown, W.M.; Royer, 
R.E. Chem. Biol. Interact., 2001, 130–132, 549. 
29 
 
40. Szwergold, B.S.; Howell, S.; Beisswenger, P.J. Diabetes, 2001, 50, 
2139. 
41. Thornalley, P.J. Biochem. J., 1990, 269, 1. 
42. Thornalley, P.J. Chem. Biol. Interact., 1998, 111, 137. 
43. Westwood, M. E.; Thornalley, P.J. J. Protein Chem., 1995, 14, 359. 
44. Schmidt, A.M.; Hori, O.; Brett, J. Arterioscler. Thromb., 1994, 4, 1521. 
45. Li, Y.M.; Mitsuhashi, T.; Wojciehowicz, D. Proc. Natl. Acad. Sci., 1996, 
93, 11047. 
46. Stitt, A.W.; He, C.J.; Vlassara, H. Biochem. Biophys. Res. Comm., 1999, 
256, 549. 
47. Vlassara, H. Science, 1988, 240, 1546. 
48. Kirstein, M.; Aston, C.; Hintz, R.; Vlassara, H.J.; Clin. Invest., 1992, 90, 
439. 
49. Skolnik, E.Y. J. Exp. Med., 1991, 174, 931. 
50. Doi, T. Proc. Natl. Acad. Sci., 1992, 89, 2873. 
51. Ahmed, N.; Thornalley, P.J. Ann. NY Acad. Sci., 2005, 1043, 260. 
52. Zeng, J.; Davies, M.J. Chem. Res. Toxicol., 2005, 18, 1232. 
53. Li., J.; Gobe, G. Nephrology, 2006, 11, 428. 
54. Inoguchi, T.; Sonta, T.; Tsubouchi, H.; Etoh, T.; Kakimoto, M.; Sonoda, N.; 
Sato, N.; Sekiguchi, N.; Kobayashi, K.; Sumimoto, H.; Utsumi, H.; 
Nawata. H. J. Am. Soc. Nephrol., 2003, 14, S227. 
55. Phillips, A.O. Curr. Diab. Rep., 2003, 3, 491. 
30 
 
56. Brownlee, M. Nature, 2000, 414, 813. 
57. Schena, F.P.; Gesualdo, L. J. Am. Soc. Nephrol., 2005, 16, S30. 
58. Tan, A.l.; Forbes, J.M.; Cooper, M.E. Semin. Nephrol., 2007, 27, 130. 
59. Hirai, A.; Yasuda, H.; Joko, M.; Maeda, T.; Kikkawa, R. J. Neurol. Sci., 
2000, 172, 55. 
60. Yagihashi, S.; Yamagishi, S.I.; Wada, R.; Baba, M.; Hohman, T.C.; 
Yabe-Nishimura, C. Brain, 2001, 124, 2448. 
61. Archer, D.B. Eye, 1999, 13, 497. 
62. Stitt, A.W.; Li, Y.M.; Gardiner, T.A. Am. J. Pathol., 1997, 150, 523. 
63. Clements, R.S. Jr.; Robison, W.G. Jr.; Cohen, M.P. J. Diabetes Comp., 
1998, 12, 28. 
64. Bron, A.J.; Vrensen, G.F.; Koretz, J. Intern. J Ophthol., 2000, 214, 86.  
65. Farrukh, A.S.; Sharkey, E.; Creighton, D. Exp. Eye. Res., 2000, 70, 369. 
66. Chellan, P.; Nagaraj, R.H.; Arch. Biochem. Biophys., 1999, 368, 98. 
67. Behl, C.; Davis, J.B.; Lesley, R.; Schubert, D. Cell, 1994, 77, 817. 
68. Toth, C.; Martinez, J.; Zochodne, D.W. Curr. Mol. Med., 2007, 7, 766. 
69. Münch, G.; Thome, J.; Foley, P.; Schinzel, R.; Riederer, P. Brain Res. 
Rev., 1997, 23, 134. 
70. Reiser, K. M. Proc. Soc. Exp. Biol. Med., 1998, 218, 23. 
71. Harding, J.J. Adv. Protein Chem., 1985, 37, 247. 
72. Hirsch, J.; Petrakova, E.; Feather, M.S.; Barnes, C.L. Carbohydr. Res., 
1995, 267, 17. 
31 
 
73. Hirsch, J.; Petrakova, E.; Feather, M.S. Carbohydr. Res. 1992, 232, 125. 
74. Vinson, J. A.; Howard, T.B. J. Nutr. Biochem., 1996, 7, 659. 
75. Hud, E.; Cohen, M.P. Clin. Chim. Acta., 1989, 185, 157. 
76. Brownlee, M.; Vlassara, H.; Kooney, A.; Ulrich, P.; Cerami, A. Science, 
1986, 232, 1629. 
77. Brownlee, M Diabetes, 1994, 43, 836. 
78. Voziyan, P.A.; Metz, T.O.; Baynes, J.W.; Hudson, B.G J. Biol. Chem., 
2002, 277, 3397. 
79. Voziyan, P.A.; Hudson, B.G. Cell Mol Life Sci, 2005, 62, 1671. 
80. Kass, D.A.; Shapiro, E.P.; Kawaguchi, M.; Capriotti, A.R.; Scuteri, A.; 
DeGroof, R.C.; Lakatta, E.G. Circulation, 2001, 104, 1464. 
81. Vasan, S.; Zhang, X.; Kapurniotu, A.; Bernhagen, J.; Teichberg, S.; 
Basgen, J.; Wagle, D.; Shih, D.; Terlecky, I.; Bucala, R.; Cerami, A.; 
Egan J.; Ulrich, P. Nature, 1996, 382, 275. 
82. Cameron, N.E.; Cotter, M.A. Diabet. Med., 1993, 10, 593. 
83. Seneviratne, C.; Dombi, G.W.; Liu W.; Dain, J.A. J. Inorg. Biochem., 
2011, 105, 1548. 
84. Seneviratne, C.; Narayanan, R.; Liu W.; Dain, J.A. Biochem. Biophys. 
Res. Commun., 2012, 422, 447. 
85. Rahbar, S.; Figarola, J.L. Arch. Biochem. Biophys., 2003, 419, 63.  
86. Basta, G.; Schmidt A.M.; Caterina, R.D. Cardiovasc. Res., 2004, 63, 
582. 
32 
 
87. Khalifah, R.G.; Baynes, J.W.; Hudson, B.G. Biochem. Biophys. Res. 
Commun., 1999, 257, 251. 
88. Peng, X.; Ma, J.; Chen, F.; Wang, M. Food Func., 2011, 2, 289.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
 
 
Figure 1. The initial stage of glycation resulting in the formation of a Schiff 
base and an Amadori product.  
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Figure 2. In vivo sources of dicarbonyl glycation precursors which are 
responsible for the formation of AGEs and carbonyl stress (85). 
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Figure 3. Chemical structures of currently well-defined AGE dicarbonyl 
precursors (glyoxal, 3-deoxy-glucosone and methylglyoxal), and their 
interactions with glycated proteins (86). 
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Figure 4. AGE crosslink structures formed under physiological condition 
which exhibit fluorescence absorbance. [Lys] indicates to lysine residue and 
[Arg] indicates to arginine (5).  
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Figure 5. Chemical structures of some of the most important and 
well-studied non-crosslinking AGEs including pyrraline, 1-carboxyalkyl 
lysine and imidazolone A and B. [Lys] indicates to lysine residue and [Arg] 
indicates to arginine (5).  
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Figure 6. Pathways for the formation of Nε-carboxymethyl lysine in vivo (87). 
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Figure 7. Intracellular accumulation of AGEs damages target cells through 
receptor-mediated pathway, in which the glycated plasma proteins bind to 
AGE receptors on cell surface, inducing cell signaling and oxidation stress 
(56). 
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Figure 8. Structures of reactive oxygen species (ROS). 
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Figure 9. Pathways for the generation of ROS which lead to oxidative stress 
(85). 
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Figure 10. Schematic of in vivo glycation reactions and common targets for 
AGE inhibition in the pathways (87). 
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Figure 11. Structures of some synthetic anti-glycation agents which act as 
dicarbonyl compound scavengers (88). 
 
 
 
 
 
 
 
44 
 
 
 
Figure 12. Structures of some typical AGE breakers which reduce the 
damage of glycation (88). 
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Abstract 
Melamine (1,3,5-triazine-2,4,6-triamine) is employed in the manufacture of 
plastics, laminates and glues, yet, it has been found sometimes added 
illegally to dairy products to artificially inflate foods’ protein content. In 2008, 
dairy products adulterated with melamine were blamed for the death of 
several infants in China, a situation that forced Beijing to introduce stricter 
food safety measures. The objectives of this study were threefold: 1) to 
investigate, using UV and fluorescence spectrometry, the susceptibility of 
the amine groups of melamine to glycation with D-galactose, D-glucose and 
lactose, sugars commonly found in milk, 2) to study the rate and extent of 
melamine’s glycation with methylglyoxal, glyoxal and DL-glyceraldehyde, 
three highly reactive metabolites of D-galactose, D-glucose and lactose, 
and 3) to characterize, using HPLC and mass spectrometry, the Advanced 
Glycation Endproducts (AGEs) of melamine with sugars found commonly in 
milk and their metabolites. Incubation of D-galactose, D-glucose and 
lactose with melamine revealed that D-galactose was the most potent 
glycator of melamine, followed by D-glucose, then lactose. Methylglyoxal, 
glyoxal, and DL-glyceraldehyde glycated melamine more extensively than 
D-galactose, with each yielding a broader range of AGEs. The 
nonenzymatic modification of melamine by sugars and sugar-like 
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compounds warrants further investigation, as this process may influence 
melamine’s toxicity in vivo. 
Keywords: melamine; glycation; D-galactose; methylglyoxal; AGEs 
 
1.0. Introduction 
In 2008, many dairy products in China were found to be adulterated with the 
chemical melamine, a situation that contributed to the death and 
hospitalization of children and a massive recall of many food products (1 - 5). 
The adulteration of food products with melamine unfortunately continues to 
this day in China, despite the government’s ongoing efforts to halt this 
practice. 
Melamine is an organic base with a 1,3,5-triazine backbone. That is 
essentially a trimer of cyanamide with three amino groups attached to its 
hexagonal structure (see figure 1). The three amino groups suggest that 
melamine should be a target for nonenzymatic glycation by the Maillard 
reaction. 
The Maillard reaction is a non-enzymatic browning reaction that involves a 
series of steps with the reactants typically including a reducing sugar and a 
protein. In the initial phase of the Maillard reaction, the carbonyl group of the 
reducing carbohydrate condenses with the free amino groups on the protein 
to form reversible glycosylamines, which are then converted to more stable 
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Amadori products. Once formed, these Amadori products can with time 
undergo dehydration, cyclization, oxidation, and rearrangement to form a 
polymorphic group of compounds collectively referred to as Advanced 
Glycation Endproducts (AGEs) (6 - 8).  
Ever since its description in 1912, the Maillard reaction has continued to be 
a topic of research interest. One reason for this focus on the Maillard 
reaction is that it cuts across several disciplines with nutrition science and 
medicine serving as examples. For researchers in nutrition science, 
harnessing the Maillard reaction has allowed for control of food flavor, food 
aroma, food coloring, and food texture (9 - 10). For researchers in clinical 
medicine exploring the Maillard reaction has meant gaining a deeper insight 
into the biochemistry of diabetes and its chronic complications including 
renal failure, cataract formation and atherosclerosis (11 - 13). 
Studies in our laboratory and those of others have shown that AGEs can 
form both in vitro and in vivo, and that besides proteins can involve other 
free amino containing molecules such as DNA, RNA, lipids, amino acids 
and amino sugars (14 - 17). The objectives of this study were three fold: first, 
to determine if melamine can be glycated by by D-galactose, D-glucose and 
lactose, three sugars that are present in milk; second, to compare the 
glycation levels of melamine with D-galactose, D-glucose and lactose; third, 
to determine if melamine can nonenzymatically react with methylglyoxal, 
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glyoxal and DL-glyceraldehyde, three highly reactive metabolic products of 
D-galactose, D-glucose and lactose (15; 18 - 21). 
In this report, we show that melamine is susceptible to glycation by 
D-galactose and demonstrate the ability of melamine to form AGEs. We 
also describe the nonenzymatic glycation of melamine with methylglyoxal, 
glyoxal, and DL-glyceraldehyde, the three more reactive metabolites of milk 
sugars. Emphasis is also placed on the characterization of the AGEs of 
melamine by HPLC, UV, fluorescence and mass spectrometry.  
 
2 Materials and methods 
2.1 Chemicals and supplies 
Analytical grade D-galactose, D-glucose, lactose, glyoxal, methylglyoxal, 
DL-glyceraldehyde and melamine were purchased from Sigma Chemical 
Co. (St. Louis, MO). Disposable UV-transparent cuvettes (12.5 mm X12.5 
mm X 36 mm) and HPLC analytical grade solvents were obtained from 
Thermo Fisher Scientific (Rockford, IL). Reverse phase HPLC columns 
containing C8 silica resins were obtained from Agilent Technologies 
(Chelmsford, MA) with all other HPLC supplies from Phenomenex 
(Torrance, CA). 
 
2.2 Preparation of reaction mixtures 
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2.2.1 Reaction of lactose, D-glucose and D-galactose (milk sugars) with 
melamine: Stock solutions of melamine (5 mM) and sugar (300 mM) 
were prepared in 0.1 M phosphate buffer, pH 6.7. Final incubation 
mixtures included variable amounts of melamine (0.2, 1, or 2.5 mM) 
with a set concentration of D-glucose, D-galactose or lactose (150 
mM). Blanks included melamine alone (0.2, 1 or 2.5 mM) or sugar 
alone (lactose, D-glucose or D-galactose) each at a final 
concentration of 150 mM. Freshly mixed sugars with melamine 
served as the control solutions. All reaction mixtures and blanks were 
incubated in the dark in a shaking water bath for 2 hours at variable 
temperatures (40 °C, 50 °C, 60 °C, 70 °C, 80 °C and 90 °C). After 
incubation, samples were placed at -20 °C until analyzed.  
2.2.2 Reaction of methylglyoxal, glyoxal and DL-glyceraldehyde with 
melamine: Unless otherwise indicated, all reactions were conducted 
in 0.2 M phosphate buffer, pH 7.2, containing 0.02% sodium azide. 
Stock solutions of melamine (5 mM), methyglyoxal (40 mM), glyoxal 
(40 mM) and DL-glyceraldehyde (40 mM) were prepared by 
separately dissolving each in the 0.2 M phosphate buffer. Final 
incubation mixtures included variable amounts of methylglyoxal, 
glyoxal or DL-glyceraldehyde (5 or 20 mM) with different 
concentrations of melamine (0.2, 1, or 2.5 mM).  Blank solutions 
included methylglyoxal, glyoxal or glyceraldehyde alone (5 mM or 20 
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mM), or melamine alone (0.2 mM, 1 mM or 2.5 mM). Controls 
included non-incubated freshly mixed solutions of each aldehyde 
(methylglyoxal, glyoxal or DL-glyceraldehyde) with melamine. All 
reaction mixtures and blank solutions were incubated in the dark at 
37 °C in a shaking water bath for 30 days. After incubation, samples 
were placed at -20 °C until analyzed.  
 
2.3 UV and fluorescence spectroscopy 
UV readings were obtained at a wavelength of 240 nm with an UltroSpec 
2100 instrument (Biochrom Ltd, Cambridge, UK). Fluorescence 
measurements were made at respective excitation and emission 
wavelengths of 260 nm and 380 nm using a Spectra Max M2 spectrometer 
(Molecular Devices, Sunnyvale, CA). All readings were obtained in 
thermostatically controlled cuvettes that were maintained at 25±1 °C. The 
above excitation and emission wavelengths were determined optimal for 
detecting melamine AGEs.  
 
2.4 High-performance liquid chromatography 
Each HPLC run was performed in triplicate using a Hitachi system (San 
Jose, CA, USA) equipped with a low-pressure gradient pump (L-2130), a 
four-channel degasser, a sequential auto sampler (L-2200), and a high 
sensitivity diode-array detector (190–800 nm) (L-2455). AGE species were 
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separated on a C8 reverse phase HPLC column (5 μm×4.6 mm×150 mm) 
and monitored at 240 nm. Mobile phase consisted of a 92% solution of 10 
mM citrate heptane sulfonate buffer, pH 3.0 and 8% acetonitrile. An 
isocratic condition was applied for 15 min at a constant flow rate of 1.00 ml 
min-1. Prior to HPLC analysis, all solvents were filtered with a 0.45 μm 
membrane (Millipore, Billerica, MA, USA), degassed for 15 min, and 
centrifuged.  
 
2.5 Mass spectrometry 
Mass spectrometry studies were performed on a ThermoFinnigan LCQ 
mass spectrometer (ThermoScientific, Waltham, MA) equipped with an 
electrospray ionization source and a quadrupole ion trap mass analyzer. 
Samples were diluted into a solvent consisting of 50/50 (v/v) 0.1% acetic 
acid in water/acetonitrile and directly infused into the electrospray source 
using a capillary syringe pump at a flow rate of 3 μL min-1. Nitrogen was 
used as the sheath gas (setting at 60), and ultrapure helium was used as 
the collision gas. The ion spray voltage was set as 4.5 kV and the capillary 
temperature was 210 °C. The mass spectrometer was set to function in the 
positive ion mode with parameters optimized during direct infusion of 
caffeine standards with solvent. Samples were analyzed by MS and tandem 
mass spectrometry (CID fragmentation with Helium) favoring isolation and 
fragmentation of singly charged ions. The ESI/MS system was operated 
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with the Xcalibur software (version 2.0, ThermoFinnigan), with the same 
software used also for data analysis.   
 
3 Results 
Figure 2a and 2b show the time course of melamine’s glycation with 
D-glucose, D-galactose and D-lactose under temperature and pH conditions 
employed in the manufacture of powdered milk products. The amounts of 
D-glucose, D-galactose and lactose were adjusted to actual concentrations 
of the sugars in unprocessed milk and lactose free milk formulas [22]. At pH 
6.7 and 80 °C for 120 min, D-glucose and D-lactose were found to be poor 
glycators of melamine yielding UV and fluorescence spectral profiles that 
were nearly superimposable. Under equivalent incubation conditions, 
mixtures of D-galactose and melamine yielded higher fluorescence readings 
demonstrating that relative to D-glucose and D-lactose, D-galactose was a 
more effective glycator of melamine. As expected, the blank solutions and 
controls yielded no changes in their fluorescence, confirming that for 
glycation to occur, both sugar and melamine had to be in the same reaction 
mixture and incubated over time. 
The pronounced reactivity of D-galactose relative to D-glucose may be 
explained by the enhanced general instability of the hemiacetal ring of 
D-galactose, which in solution renders the molecule more prone to an 
open-chain configuration [23, 24]. Thus, with a higher percentage of the 
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sugar existing in an open ring structure than D-glucose, D-galactose 
becomes more vulnerable to nucleophilic attack by the amino groups on 
melamine [23, 24]. This phenomenon may also explain galactose’s higher 
reactivity than D-lactose since as a disaccharide, lactose contains 
D-glucose at it reducing end.  
Figures 3A, 3B and 3C display the respective HPLC elution profiles of 
mixtures of melamine incubated with D-galactose, D-glucose and lactose at 
80 °C for 1 hour. Figure 3D shows the HPLC elution profiles of solutions 
containing melamine alone (blank), and melamine freshly added to 
D-galactose, D-glucose or D-lactose (controls). Melamine alone eluted as 
one prominent peak with a retention time (Rt) of 7.40 min. Each of the 
control mixtures yielded an elution profile identical to the blank, showing one 
peak coincident to where melamine eluted (Rt 7.40 min).  
The HPLC chromatograms in figures 3A to 3D revealed two important 
things: 1) that glycation was a time dependent process requiring the 
presence of both melamine and sugar, and 2) that D-galactose was a more 
potent glycator of melamine than D-glucose and D-lactose, a finding 
consistent with the fluorescence data in figure 2. Incubation mixtures of 
D-galactose with melamine yielded three distinct AGE products by HPLC. 
Of the bands corresponding to the AGE products, one eluted with a 
retention time of 3.85 min, one at 4.49 min and one at 5.08 min (figure 3A). 
A fourth band appearing at a retention time of 7.40 min corresponded to the 
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fraction of melamine that did not condense with D-galactose. Integration of 
the band areas revealed that with D-galactose as the glycating sugar 32.1% 
of melamine was nonenzymatically modified; i.e., in contrast to 12.3% with 
D-glucose and 6.3% with D-lactose. Other results revealed that reducing the 
incubation temperatures, reduced the extent glycation of melamine and the 
number of AGEs of melamine in the reaction mixtures. Figures 4A, 4B and 
4C exemplify this behavior with D-galactose as the model glycating agent.  
Tables I displays the changes in UV absorption readings of incubation 
mixtures of melamine with methylglyoxal, glyoxal and DL-glyceraldehyde 
(hereon referred to as “aldehydes”) at 37 °C covering different time intervals. 
Increasing incubation time enhanced the AGE formation of melamine with 
the highest levels of glycation achieved when aldehyde concentrations were 
adjusted to 20 mM. A close scrutiny of the table confirmed the earlier 
observations that the extent glycation of melamine was a time dependent 
process relatable to the chemistry and concentration of the aldehydes in the 
incubation mixtures. Increases in the aldehyde concentrations prompted 
AGE formation, with methylglyoxal yielding the highest UV absorbing 
products followed by glyoxal then DL-glyceraldehyde (figures 5a and 5b). 
Increases in melamine concentration in the presence of set amounts of the 
various aldehydes also promoted AGE formation, demonstrating that the 
rate of glycation reaction was dependent on both the concentrations of 
melamine and the various aldehydes (data not shown). Using variable 
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amounts of melamine in the incubation mixtures had no effect on the 
intensity order of the glycated compounds that were formed with 
methylglyoxal and DL-glyceraldehyde, once again, producing AGEs with the 
highest and lowest UV intensities, respectively. 
Table II and figures 6A, B and C show the HPLC retention times of the 
various AGEs of melamine with methylglyoxal, glyoxal and 
DL-glyceraldehyde at 37 °C over 30 days. Included in Table II is also the 
number of AGE products and their percent amount relative to the total AGEs 
in each incubation mixture over time. The band eluting at retention time 7.4 
min was assigned to nonglycated melamine; an observation based on the 
HPLC elution profiles of both the blank and control solutions (figure 6D). 
Analysis of the data in Table II showed that with methylglyoxal there were 
more AGE products formed than with glyoxal and DL-glyceraldehyde, with 
DL-glyceraldehyde yielding the lowest number of AGEs. A further 
evaluation of the results in Table II revealed that glyoxal was the most active 
glycator of melamine followed by methyglyoxal then DL-glyceraldehyde 
(figure 7).  
Figures 8 shows the mass spectral profiles of 2.5 mM melamine incubated 
with 20 mM methylglyoxal at 37 °C for 30 days. Mass spectral analysis of 
melamine alone yielded one primary peak located at m/z 127 (data not 
shown). In reaction tubes containing melamine and methylglyoxal, the main 
product ions were at m/z 199, 271, and 343. The product with m/z 199 
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corresponded to the addition of one methylglyoxal monomer (Δ m/z 72) to 
melamine, whereas those with m/z 271 and 343 corresponded to the 
condensation of two and three monomers.  
Figure 9a-c show the CID mass spectrum for methylglyoxal’s primary 
product ion at m/z 199 (figure 9a), 271(figure 9b) and 343 (figure 9b) with 
the main fragmentation pattern revealing a loss in water (-18 Da) and a loss 
in CO (-28 Da). The absence of a peak at m/z 155 indicated that no 
carboxylic acid functional group was present. This conclusion was further 
supported by the absence of a peak at m/z 197 after repeated analysis of 
the sample in the negative ion mode. The product ion at m/z 199 appears to 
contain a hemiaminal structure without loss of water forming a Schiff base at 
pH 7.2.  
For the reaction with 20 mM glyoxal (figure 10), a prominent peak at m/z 
185 was observed. This ion corresponded to the addition of one glyoxal 
monomer (Δ m/z 58) to melamine. Figure 11a shows the CID mass 
spectrum for glyoxal product ion at m/z 185 with the main fragmentation 
pattern, again, showing a loss in water (-18 Da), and a loss in CO (-28 Da). 
This suggests that the reaction of melamine with glyoxal was similar to that 
of methylglyoxal in forming a hemiaminal structure.  
In contrast to glyoxal and methylglyoxal, glyceraldehyde condensed with 
melamine through a Schiff base/Amadori reaction, forming a product ion at 
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m/z 199 (figure 12). The mass spectrometric profile of D-galactose with 
melamine was more difficult to interpret (figure 14); however, the product 
ion at m/z 289 suggested the occurrence of Schiff base formation between 
the anomeric carbon of D-galactose with one of the amino groups of 
melamine. This result was confirmed by CID fragmentation of the product 
ion at 289 (figure 15a). The additional ions indicated that more than one 
D-galactose monomer could have condensed with melamine with the latter 
then rearranging to yield multiple products. 
Figures 16A thru 10D display the proposed structures consistent with the 
mass spectral data for the primary products formed in incubation mixtures 
containing melamine with methylglyoxal, glyoxal, DL-glyceraldehyde and 
D-galactose. A detailed analysis of the predominant product ions generated 
from the reaction of melamine with methylglyoxal (figure 8) leads to the 
postulated mechanism pathway for the formation of AGEs seen in Figure 17. 
It should be noted that a portion of the signal for ion at m/z 181 in the mass 
spectrum (figure 8) could be arising from the dehydration of the ion at m/z 
199 in the electrospray source. 
Other findings revealed that increases in pH promoted melamine AGEs with 
D-galactose and methylglyoxal (figure 18). This effect of pH on the glycation 
of melamine was not surprising since increases in pH have been shown to 
promote Schiff base formation (15 - 16).  
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4 Discussion 
Melamine is a chemical that has been employed in the manufacture of 
adhesives, laminates, plastics, floor tiles, kitchenware, and commercial 
filters. Yet, it has been also used as an additive to artificially boost a food’s 
protein content, creating a lucrative market for edibles believed to be of 
nutritious value. The deliberate adulteration of foods with melamine would 
not have surfaced, if it wasn’t for the recent events of 2007 and 2008. In 
2007, there was an outbreak of acute renal failure in cats and dogs in the 
United States that resulted in the death of hundreds of animals across the 
country (25). Investigations into the etiology of the outbreak traced the 
problem to gluten, an ingredient in pet foods exported from China found 
contaminated with ‘scrap melamine’ (26 - 27). ‘Scrap melamine’ is a 
byproduct of melamine industry that in addition to melamine contains 
variable amounts of cyanuric acid including different oxytriazines (28). 
Melamine alone has been shown to cause no or little toxicity in animals (29 - 
30); however, when combined with cyanuric acid, the two chemicals can 
trigger the formation of kidney stones which ultimately leads to renal failure 
(29 - 31).  
In 2008, the melamine crisis expanded from a pet problem to a human 
problem when ‘scrap melamine’ was discovered in infant’s formulas, 
powdered milk and other dairy products; blamed for the sickening of 
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countless children and the death of at least several infants in China (1; 3; 
32). The melamine contamination was also found in non-dairy food products 
made in China such as candies, egg products and non-dairy creamers, 
some of which have been exported to other countries (29; 31 - 32). The 
deliberate adulteration of edibles with melamine caused an unprecedented 
hysteria throughout China forcing Beijing to adopt stricter food safety 
regulations and to step up inspection of its dairy industry. The crisis of 2008 
also triggered urgency for new standards to be set for tolerable daily levels 
of melamine. For instance, in the US, the FDA has now set the limit from 
0.63mg to 0.063 mg per kg of body mass, whereas in Europe the limit now 
stands at 0.2 mg (2; 29; 31). 
Melamine is rich in nitrogen and contains three amino groups which form 
part of its hexagonal structure (figure1). These amino groups make 
melamine a target for glycation as we have shown here in this study. Our 
work with melamine revealed four important findings. First, it demonstrated 
that melamine can non-enzymatically react with sugars most abundant in 
milk and their metabolites. Second, it revealed that glycated products of 
melamine can with time form AGEs that could be readily resolvable by 
HPLC. Third, the observation was made that not all sugars and aldoses 
reacted at the same rate and extent with melamine and that increased 
temperatures and pH accelerated AGE formation. Lastly, mass 
spectrometric data revealed that glycation of melamine occurred via the 
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Amadori pathway yielding different AGE products with methylglyoxal, 
glyoxal, DL-glyceraldehyde and D-galactose.  
At present, there is little information on the long term toxicity of melamine 
and human consumption, and there is practically no data on the toxicity of 
glycated melamine in vivo. The high reactivity of melamine with milk sugar 
metabolites suggests that the immediate and long term toxicity of melamine 
may not only be related to its interactions with cyanuric acid, but may be 
caused also by its Maillard products.  
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List of figures: 
 
 
Figure 1. Chemical structure of melamine (1,3,5-triazine-2,4,6-triamine). 
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Figure 2a. Time course UV spectral profiles of reaction mixtures containing 
150 mM milk sugar (D-galactose, D-glucose or) lactose with 1 mM of 
melamine at 80 °C for 2 hours. Blank solutions were incubated under 
identical conditions as above and included either sugar (150 mM) alone, or 
melamine alone (1 mM). All points represent the average of triplicate 
measurements. Every reading was compared with the highest reading set at 
100%. Excitation and emission wavelengths were set at 260 nm and 380 
nm, respectively. 
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Figure 2b. Time course fluorescence spectral profiles of reaction mixture 
containing 150 mM milk sugar (D-galactose, D-glucose or lactose) with 
1mM melamine at 80 °C for 2 hours. Blank solutions were incubated under 
identical conditions as above and included either sugar (150 mM) alone, or 
melamine alone (1 mM). All points represent the average of triplicate 
measurements. Every reading was compared with the highest reading set at 
100%. Excitation and emission wavelengths were set at 260 nm and 380 
nm, respectively. 
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Figure 3. HPLC elution profile of melamine (1 mM) after 1 hour of incubation 
at 80 °C with 150 mM D-galactose (A), D-glucose (B) and lactose (C). 
Control reaction mixtures contained freshly mixed solutions of sugar with 
melamine (D). Repeat chromatographic studies by HPLC revealed no 
significant difference in the elution profiles and the retention times of the 
different AGEs. 
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Figure 4. HPLC elution profile of melamine with D-galactose in phosphate 
buffer, pH 6.7 after the incubation of the two reactants for 1 hour at 90 °C 
(A), 70 °C (B), and 40 °C (C). Repeat chromatographic studies by HPLC 
revealed no significant differences in the elution profiles and the retention 
times of the different AGEs in the above reaction mixtures. 
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Figure 5 a and 5 b show the UV absorbance profiles of incubation mixtures 
containing varied amounts of methylglyoxal, glyoxal and DL-glyceraldehyde 
(5 mM in a and 20 mM in b) with set concentrations of melamine (2.5 mM) in 
phosphate buffer, pH 7.2 at 37 °C for 30 days. Blank solutions were 
incubated as above with either aldehyde alone (5 mM and 20 mM), or 
melamine alone (2.5 mM). All UV readings were subtracted from the blank 
readings. 
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Figure 6. HPLC elution profiles of melamine (2.5 mM) with methylglyoxal 
(20 mM) [A], glyoxal (20 mM) [B] and DL-glyceraldehyde (20 mM) [C] after 
30 days incubation at 37 °C. Figure 6D shows HPLC elution profile of 
melamine alone (2.5 mM) or melamine freshly incubated with aldehydes (20 
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mM each). All separations were performed on C8 reverse phase HPLC 
column (5 μm×4.6 mm×150 mm) as described previously. Repeat 
chromatographic studies by HPLC revealed no significant differences in the 
elution profiles and the retention times of the AGE peaks. 
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Figure 7. The order of reactivity of methylglyoxal, glyoxal and 
DL-glyceraldehyde with melamine. Glyoxal was the most reactive glycator 
of melamine followed by methylglyoxal then DL-glyceraldehyde. The 
percentages of nonglycated melamine were calculated on the basis of the 
ratio of HPLC band areas of nonglycated melamine to total band areas in 
each chromatograph. All values in the figure are the average of triplicate 
measurements. The variation of each set of triplicate readings is less than 
1%. 
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Figure 8. Mass spectral analysis of solutions of melamine [2.5 mM] 
incubated with methylglyoxal [20 mM] (A) at 37 °C for 30 days.  
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Figure 9a. CID mass spectra of mass spectrum profile in figure 8 recorded 
on the (M+H)+ ion at m/z 199. 
 
Figure 9b. CID mass spectra of mass spectrum profile in figure 8 recorded 
on the (M+H)+ ion at m/z 271 
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Figure 9c. CID mass spectra of mass spectrum profile in figure 8 recorded 
on the (M+H)+ ion at m/z 343. 
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Figure 10. Mass spectral analysis of solutions of melamine [2.5 mM] 
incubated with glyoxal [20 mM] at 37 °C for 30 days. 
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Figure 11a. CID mass spectra of mass spectrum profile in figure 10 
recorded on the (M+H)+ ion at m/z 185. 
 
Figure 11b. CID mass spectra of mass spectrum profile in figure 10 
recorded on the (M+H)+ ion at m/z 244. 
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Figure 11c. CID mass spectra of mass spectrum profile in figure 10 
recorded on the (M+H)+ ion at m/z 261. 
 
Figure 11d. CID mass spectra of mass spectrum profile in figure 10 
recorded on the (M+H)+ ion at m/z 276. 
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Figure 12. Mass spectral analysis of solutions of melamine [2.5 mM] 
incubated with DL-glyceraldehyde [20 mM] (C) at 37 °C for 30 days. 
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Figure 13a. CID mass spectra of the (M+H)+ ion for DL-glyceraldehyde 
melamine product at m/z 199. 
 
Figure 13b. CID mass spectra of the (M+H)+ ion for DL-glyceraldehyde 
melamine product at m/z 271. 
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Figure 13c. CID mass spectra of the (M+H)+ ion for DL-glyceraldehyde 
melamine product at m/z 341. 
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Figure 14. Mass spectral analysis of solutions of 2.5 mM melamine with 150 
mM D-galactose at 80 °C incubated for 1 hour. 
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Figure 15a. CID mass spectra of the (M+H)+ ion for D-galactose melamine 
product at m/z 289. 
  
Figure 15b. CID mass spectra of the (M+H)+ ion for D-galactose melamine 
product at m/z 365. 
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Figure 15c. CID mass spectra of the (M+H)+ ion for D-galactose melamine 
product at m/z 473. 
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Figure 16. Elucidation of structures consistent with mass spectrometric data 
for primary products formed in incubation mixtures containing melamine 
with methyglyoxal (A), glyoxal (B), DL-glyceraldehyde (C), and D-galactose 
(D). 
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Figure 17. Postulated pathway for the formation of melamine AGEs with 
methylglyoxal. 
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Figure 18. UV absorbance profiles of incubation mixtures of melamine (2.5 
mM) with set concentration of methylglyoxal (20 mM) in phosphate buffer 
under pH 6.0, 6.5, 7.0, 7.5, 8.0 at 37 °C for 48 h (A), or with set 
concentration of D-galactose (150 mM) in phosphate buffer under pH 6.0, 
6.5, 7.0, 7.5, 8.0 at 80 °C for 2 h (B). All readings were compared with the 
highest reading, which was set at 100%. All points represent the average of 
triplicate measurements, and every reading was found to be within 5% of its 
counterpart triplicate.  
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List of tables: 
Table I 
UV readings of incubation mixtures containing melamine (2.5 mM) and 
different aldehydes (5 mM and 20 mM) 
Methylglyoxal 
5 mM 20 mM 
Actual UV 
Reading 
% Relative Reading 
Actual UV 
Reading 
%Relative Reading 
0 d 0.000±0.000 0.000 0.000±0.000 0.000 
1 d 0.075±0.002 0.336 0.271±0.003 0.321 
2 d 0.080±0.001 0.359 0.290±0.003 0.344 
30 d 
†
0.223±0.002 1.000 
†
0.844±0.002 1.000 
Glyoxal 
5 mM 20 mM 
Actual UV 
Reading 
% Relative Reading 
Actual UV 
Reading 
% Relative 
Reading 
0 d 0.000±0.000 0.000 0.000±0.000 0.000 
1 d 0.046±0.001 0.206 0.173±0.003 0.205 
2 d 0.051±0.003 0.229 0.184±0.003 0.218 
30 d 0.116±0.001 0.520 0.366±0.004 0.434 
DL-Glyceraldehyde 
5 mM 20 mM 
Actual UV 
Reading 
% Relative Reading 
Actual UV 
Reading 
% Relative Reading 
0 d 0.000±0.000 0.000 0.000±0.000 0.000 
1 d 0.022±0.002 0.099 0.025±0.004 0.030 
2 d 0.026±0.001 0.117 0.031±0.002 0.037 
30 d 0.080±0.002 0.359 0.302±0.003 0.342 
Reaction mixtures included methylglyoxal, glyoxal and DL-glyceraldehyde (5 mM 
or 20 mM) with melamine (2.5 mM) in phosphate buffer, pH 7.2 at 37 °C for 30 
days. Blank solutions were incubated as above with either individual aldehydes 
alone, or melamine alone. All readings were subtracted from the readings of the 
blank solutions. % Relative readings were calculated based on the highest UV 
values obtained within each set of reaction mixtures (5 mM or 20 mM aldehyde) 
evaluated 
† denotes the highest UV readings in each set of incubation mixtures. 
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Table II 
Peak Retention Times and Percentages of AGE Band Areas Resulting from 
the Separation of Incubation Mixtures Containing Methylglyoxal, Glyoxal and 
DL-Glyceraldehyde with Melamine by HPLC   
 
Time 
(Day) 
* % Band Area of 
Nonglycated 
Melamine (Rt=7.4 
min) 
                                          
                                                         
 
1 2 3 4 5 6 7 8 9 10 
MG 
 
0 100.0% 
  
 
         
2 74.9% 
      
     
 
      
     
         
10 54.4% 
      
    
 
      
    
 
      
    
 
      
     
 
       
    
 
       
    
     
30 39.9% 
      
    
 
      
    
 
      
    
 
      
     
 
      
    
 
      
    
 
      
    
 
      
    
 
       
    
 
       
     
 
Gly 
0 100.0% 
 
         
2 61.6% 
      
     
          
10 29.3% 
      
    
 
      
    
 
      
     
        
30 3.5% 
      
    
 
      
     
 
      
    
 
      
     
 
      
     
 
      
     
     
GA 
0 100.0% 
 
         
2 91.9% 
      
    
 
      
    
         
10 75.9% 
      
    
 
      
    
 
      
     
 
      
    
       
30 54.5% 
      
    
 
      
     
 
      
     
 
      
     
       
 
* Denotes the fractions of nonglycated melamine eluted at retention time of 
7.4 min. 
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Abstract: 
The formation of advanced glycation endproducts (AGEs) by 
non-enzymatic glycation of protein with reducing sugar is a major 
contributor to the pathology of diabetes, Alzheimer’s disease and 
atherosclerosis. Previous study in our laboratory showed that 2 nm gold 
nanoparticles (GNPs) exhibit an inhibition effect on the formation of AGEs 
when serum albumin was glycated with DL-glyceraldehyde. The objective 
of this study was to evaluate the rate and extent of AGE formation of 
bovine serum albumin (BSA) in the presence of GNPs with varied sizes. A 
combination of UV spectrometry, HPLC and circular dichroism showed 
that only GNPs with size ranging from 2nm to 20nm inhibited the formation 
of BSA AGEs. The inhibition effect of GNPs was correlated to the overall 
surface area of nanoparticles in the solution. GNPs with higher surface 
areas were found to be better inhibitors of glycation, whereas those with 
low surface areas were less effective inhibitors. MALDI-TOF spectrum 
showed that in the presence of GNPs, BSA was less prone to be glycated 
by reducing sugar comparing to reaction mixtures absent of GNPs. The 
inhibitory effect of GNPs on non-enzymatic glycation reactions may be 
96 
 
due to the covalent bonding between gold atoms on the surface of GNP 
and ε amino groups of L-lysine residue on protein. As GNP is highly 
biocompatible and water soluble, an insight of its anti-glycation effect and 
its inhibition mechanism on the formation of AGEs might lead to a novel 
therapeutic application of GNP on reducing AGE related complications. 
 
Key Words: gold nanoparticle; glycation; AGEs; BSA; D-ribose  
 
                                    
1 Introduction 
Glycation is a non-enzymatic reaction with reactants including a 
reducing sugar and a free amino containing molecule such as protein, lipid or 
nucleic acid. The reaction initiates with a nucleophilic attack of the free 
amino group on biomolecule to the carbonyl group of a reducing sugar, 
forming an unstable Schiff base structure. The Schiff base will then 
rearrange to a more stable ketoamine known as Amadori product. Under 
physiological condition, this Amadori product can undergo series of 
irreversible chemical reactions including self-degradation and condensation 
with other proteins, leading the formation of a heterogeneous group of 
compounds referred to as advanced glycation endproducts (AGEs) [1, 2]. 
The graduate accumulation of AGEs in vivo has been implicated as a major 
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contributor to various diabetic complications including renal failure, diabetic 
atherosclerosis and cataract formation, as well as other health disorders, 
such as Alzheimer’s disease (AD) [3-5]. Abnormal built up of AGEs under 
hyperglycemia condition could trigger the generation of harmful 
inflammatory factors and reactive oxygen species, resulting in tissue 
damage. Long lived protein which has a low clearance rate tends to form 
crosslinking structures with certain type of AGEs and gradually lose its 
function in vivo. 
Since the non-enzymatic glycation of proteins is tightly related to the 
pathology of long-term diseases, the inhibitors to prevent the formation of 
AGEs have been extensively investigated over years [6-8]. The reactants 
involved in the initial stage of glycation are a common target for 
anti-glycation drug design [9, 10]. This class of inhibitors act as sugar 
competitors by interacting with target glycation amino acid residues, most 
commonly lysine and arginine, and prevent their further modification by 
reducing sugars. Two notable potential anti-glycation agent fall into this class 
include acetylating aspirin and aldehyde pyridoxal-5’-phosphate.  
Previous study in our laboratory showed that 2 nm gold nanoparticles 
(GNPs) exhibit an inhibitory effect on the formation of AGEs when Human 
Serum Albumin (HSA) was glycated by DL-glyceraldehyde [11]. GNP 
typically refers to gold colloid with a particle size ranging from one 
nanometer to several hundred nanometers. Due to its unique optical 
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property, very large surface-to volume ratio and easy modification, GNP has 
been applied in a broad range of fields including biomedicine, bio-imaging, 
material science and synthetic chemistry [12-14]. 
Proteins and amino acids are able to covalently bond to the gold atoms 
on the surface of nanoparticle through Au-S or Au-NH2 bonds [15, 16]. The 
binding of biomolecules to GNP can stabilize the particle from conjugation 
and enhance its solubility in aqueous solution as well [17]. In the meanwhile, 
free amino groups in proteins or peptides, some of which are the seeding 
sites of GNP to these biomolecules, might also be reaction sites susceptible 
to glycation by reducing sugar. This suggests that the specific covalent 
bonding of GNP to these amino groups in protein might be able to protect 
these sites from glycation. Furthermore, GNP could possibly bind to the 
glycation intermediates of protein and prevent the formation of reactive 
dicarbonyl compounds. By trapping these AGE precursors, GNP could 
stabilize and fix the protein structure from further alteration and prevent the 
formation of AGEs.  
The objective of this study was to evaluate the rate and extent of BSA 
glycation by D-ribose in the presence of spherical GNPs. A combination of 
UV spectrometry, HPLC, circular dichroism and MALDI were used to 
determine the formation of AGEs. This study emphasized also on the effect 
of different nanoparticle sizes on GNP’s inhibitory efficiency. The correlation 
between particle size, total particle surface area in solution and GNP’s 
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anti-glycation ability was evaluated by two separate experiments designated 
as experiment A and B. As GNP is highly biocompatible and water soluble, 
an insight of its anti-glycation effect and its inhibition mechanism on the 
formation of AGEs might lead to a novel therapeutic application of GNP on 
reducing AGE related complications. 
 
5 Materials and methods 
5.1 Chemicals and supplies 
Fatty acid free albumin from bovine serum (BSA) and analytical grade 
D-ribose were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, 
USA). Citrate reduced colloidal solution of spherical gold nanoparticles with 
variable sizes (2nm, 5nm and 20nm) were purchased form Ted Pella Inc. 
(Redding, CA, USA). Disposable UV-transparent cuvettes (12.5 mm X12.5 
mm X 36 mm) and HPLC analytical grade solvents were obtained from 
Thermo Fisher Scientific (Rockford, IL, USA). ZipTip pipette tips with C4 
resin and 0.22 µm filter unit were purchased form EMD Millipore Co. 
(Billerica, MA, USA). Unless otherwise indicated, all other reagents of 
analytical grade were purchased from Sigma-Aldrich Chemical Co. (St. 
Louis, MO, USA). 
5.2   Preparation of reaction mixtures 
5.2.1 Stock solutions of BSA (105 mM) and D-ribose (100 mM) were 
prepared in 0.1 M phosphate buffer, pH 7.2. Gold colloids with 
different sizes of nanoparticles (2 nm, 5 nm, 20 nm, 50 nm, 100 nm 
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and 200 nm) were suspended in water and adjusted to a final Au 
mass concentration of 0.01 mg/ml each. Blank solutions included 35 
mg/ml BSA alone, 20 mM D-ribose alone and 35 mg/ml BSA with 
different sizes of GNP without D-ribose. Controls included 35 mg/ml 
BSA incubated with 20 mM D-ribose at the absence of GNP. The 
concentration of BSA was adjusted to 35 mg/ml because this is the 
reported serum albumin concentration physiologically. The 
concentration of D-ribose was adjusted to 20 mM representing the 
blood sugar content under diabetic condition. D-ribose was chosen as 
the model glycated agent due to its greater reactivity comparing to 
D-glucose and its important role in several bio pathways related to 
carbohydrates metabolism.  
5.2.2 Experiment A: Reaction mixtures contained 35 mg/ml BSA and 20 
mM D-ribose with different sizes of GNP (2 nm, 5 nm and 20 nm) at 
set Au concentration of 0.005 mg/ml, resulting in different particle 
number and total particle surface area in each solution (Table I). All 
reaction mixtures and blanks were incubated in the dark at 37 °C in a 
shaking water bath for 21 days. After incubation, samples were 
placed at -20 °C until analyzed. Prior analysis, all samples were 
ultra-centrifuged at 1X104 rpm for 30 min and the supernates were 
further purified by ZipTip pipette with C4 resin. 
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5.2.3 Experiment B: Reaction mixtures contained 35 mg/ml BSA and 20 
mM D-ribose with different sizes of GNP (2 nm, 5 nm and 20 nm) at 
different Au mass concentrations of 0.02 mg/ml, 0.01 mg/ml and 
0.05mg/ml respectively. Such dilution resulted in an approximate 
identical total nanoparticle surface area in each solution containing 
different sizes of GNPs. All reaction mixtures and blanks were 
incubated in the dark at 37 °C in a shaking water bath for 21 days. 
After incubation, samples were placed at -20 °C until analyzed. Prior 
analysis, all samples were ultra-centrifuged at 1X104 rpm for 30 min 
and the supernates were further purified by ZipTip pipette with C4 
resin. 
5.3 UV and fluorescence spectroscopy 
UV spectrum with wavelength ranging from 200 nm to 400 nm was 
determined on an UltroSpec 2100 instrument (Biochrom Ltd, Cambridge, 
UK). Fluorescence measurements were made at respective excitation and 
emission wavelengths of 340 nm and 420 nm using a Spectra Max M2 
spectrometer (Molecular Devices, Sunnyvale, CA, USA). All samples were 
diluted 50 fold before analysis and all readings were obtained in 
thermostatically controlled cuvettes that were maintained at 25±1 °C. The 
above excitation and emission wavelengths were determined optimal for 
detecting BSA AGEs.  
5.4 Circular dichroism 
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CD analysis were performed at a Jasco J-720 spectropolarimeter 
(Tokyo, Japan) using a quartz cuvette of 1 mm path length. The instrument 
was controlled by Jasco’s Spectra Manager software. Before analysis, the 
concentration of BSA was adjusted to 0.5 mg/ml using 0.1 M phosphate 
buffer, pH 7.2. Signals were obtained in the far-ultraviolet region 
(190-250nm). A total of 10 consecutive scans with bandwidth of 1 nm, scan 
speed of 20 nm/min and response time of 2 s were averaged. The spectrums 
were then subtracted by corresponding blanks to eliminate any buffer effect.   
5.5 High-performance liquid chromatography 
Each HPLC run was performed in triplicate using a Hewlett Packard 
1050 system (Waldbronn, Germany) equipped with a low-pressure gradient 
pump, a four-channel degasser, a sequential auto sampler, a high sensitivity 
diode-array detector (190–800 nm) and a programmable fluorescence 
detector (HP 1046A). The HPLC system was operated with the ChemStation 
System from Agilent Technologies (Santa Clara, CA, USA) with the same 
software used also for data analysis.  AGE species were separated on a 
Shodex (New York, NY, USA) RSpak C18 reverse phase HPLC column (5 
μm×4.6 mm×150 mm) with 415 Å pore size. Mobile phase A consisted of 0.1% 
trifluoroacetic acid (TFA) and 1% acetonitrile (ACN) in water and mobile 
phase B consisted of 0.1% TFA and 95% ACN in water. A linear gradient 
from 20% to 60% of mobile phase B was applied in 25 minutes at a constant 
flow rate of 1.0 ml/min. Prior to HPLC analysis, all solvents were degassed 
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and sonicated for 15 min. All samples were filtered with a 0.22 μm 
membrane, degassed and centrifuged.   
5.6 Preparation and analysis of intact HSA by MALDI-TOF MS 
All samples were purified with C4 ZipTips and analyzed on a Bruker 
Autoflex MALDI–TOF (time-of-flight) mass spectrometer (Bruker Daltonics, 
Billerica, MA, USA). Prior to analysis, the protein samples (0.6 μl) were 
mixed with a 50% aqueous acetonitrile solution (0.6 μl) of saturated sinapinic 
acid containing 0.05% trifluoroacetic acid (TFA) as matrix, spotted onto a 
stainless steel sample plate, and allowed to air dry. Spectra were acquired in 
linear TOF mode with a 550 ns delay in the m/z range from 20,000 to 80,000. 
Each spectrum was the sum of 500 single laser shots randomized over 10 
positions within the same spot (500/50). Analysis of data was performed 
using FlexAnalysis and ClinProTools (Bruker Daltonics). 
 
3. Results 
Figure 1 displays the respective UV spectral profiles of reaction 
mixtures in experiment A after 21 days incubation in dark at 37 °C. It should 
be noted that spherical GNPs with particle diameter larger than 20 nm (50 
nm, 100 nm and 200 nm) aggregated with BSA after two to three days 
incubation, forming insoluble precipitants in phosphate buffer. Thus only 2 
nm, 5 nm and 20 nm GNPs which retained their nanoparticle properties 
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without aggregating with BSA during incubation were evaluated in the 
following study.  
Profiles in figure 1 from top to bottom are a) 35 mg/ml BSA incubated 
with 20 mM D-ribose at the absence of GNP, b) 35 mg/ml BSA glycated by 
20 mM D-ribose at the presence of 20 nm GNP, c) 35 mg/ml BSA glycated 
by 20 mM D-ribose at the presence of 2 nm GNP, d) 35 mg/ml BSA glycated 
by 20 mM D-ribose at the presence of 5 nm GNP and e) 35 mg/ml BSA 
incubated in buffer alone. The UV spectrum scans ranged from 250 nm to 
400 nm in each profile. Comparing to BSA blank, reaction mixture containing 
BSA and D-ribose showed dramatic increase in UV absorbance intensity 
after 21 days incubation, yielding a peak with the maximum absorbance at 
around 280 nm (profile a). Aromatic rings are known as the primary reason 
for the absorbance peak at 280 nm and the increased BSA UV intensity at 
280 nm revealed the formation and accumulation of aromatic AGEs. As a 
result the increase in UV absorbance intensity at 280 nm could be used to 
evaluate the extent of BSA glycation. Comparing to reaction mixture 
containing BSA and D-ribose alone, BSA glycated in the presence of GNPs 
(profile b, c and d) showed significant reduction in UV intensity at 280 nm 
after 21 days incubation.  
Though the absorbance measurements at 280 nm in profiles b, c and d 
all decreased noticeably comparing to control reaction in profile a, the extent 
of the reduction in each solution varied. Among three incubation mixtures of 
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different sizes of nanoparticles, reaction with 5 nm GNPs showed the lowest 
UV absorbance yielding a value of 0.151 at wavelength of 280 nm. In 
comparison, control group without the treatment of GNP had a much higher 
UV intensity at 280 nm valued 0.384. Followed by 5 nm GNP solution, 
sample with 2 nm GNP exhibited the second lowest UV reading (λ280=0.180) 
while sample with 20 nm GNP showed the highest UV intensity among the 
three GNP containing mixtures (λ280=0.269). Previous study in our lab 
demonstrated that increase in nanoparticle numbers in reaction solution was 
directly correlated to its inhibitory efficiency against glycation, probably due 
to the increased available binding area on the surface of GNP, which could 
mask protein’s glycation sites. Adjusting Au mass concentration in profile b, 
c and d to the same mass value of 0.05 mg/ml resulted in a different particle 
number and total particle surface area in each solution. The value of total 
particle surface area in unit volume (ml) was obtained by multiplying the 
particle number in one unit volume (ml) with the single particle surface area 
(nm2). According to table I, 5 nm GNP solution had the highest total particle 
surface area in solution, followed by 2 nm GNP and then 20 nm. Interestingly, 
this sequence corresponded to the order of their anti-glycation efficiency that 
5 nm GNP showed the most reduction on the formation of AGEs while 20 nm 
the least.  
To further evaluate the correlation between nanoparticle size, total 
particle surface area in solution and GNP’s anti-glycation ability, we 
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conducted experiment B. In this separate study, we used the same blank 
and control samples as experiment A, while adjusted the Au mass 
concentration to 0.02 mg/ml, 0.01 mg/ml and 0.05 mg/ml for 2 nm GNP, 5 nm 
GNP and 20 nm GNP solutions respectively, resulting in a same particle 
surface area in all three GNP solutions. Figure 2 displays the UV absorbance 
spectrums of reaction mixtures in experiment B and  profiles from top to 
bottom are: a) 35 mg/ml BSA incubated with 20 mM D-ribose at the absence 
of GNP, b) 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 20 
nm GNP, c) 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 5 
nm GNP, d) 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 2 
nm GNP and e) 35 mg/ml BSA incubated in buffer alone. BSA glycated by 
D-ribose without the treatment of GNPs again yielded the highest UV 
intensity while BSA blank showed the lowest. However, 2 nm GNP and 5 nm 
GNP revealed a less inhibitory effect against glycation comparing to GNP 
solutions in experiment A, yielding UV spectral profiles that were nearly 
superimposable to that of 20 nm GNP. This suggested that all three GNP 
samples which had the same total nanoparticle surface areas exhibited 
similar ant-glycation abilities, regardless of the difference in their particle 
sizes and Au mass concentrations. 
Advanced glycation of BSA not only produces aromatic AGEs that can 
be detected by UV absorbance, but also alters proteins secondary structure 
whose change can be monitored by circular dichroism in the far-UV spectral 
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region (190-250 nm). The secondary structure of BSA is composed of about 
67% α-helix structure, so BSA conformation change was determine by 
monitoring the loss of α-helix structure in each sample. Figure 3 shows CD 
spectrum profiles for experiment A in the far-UV spectral region and figure 4 
shows the CD data for samples in experiment B. The CD spectrum for intact 
BSA without the treatment of reducing sugar and GNPs featured a 
well-defined helical pattern, with characteristic double dip at 205 nm and 222 
nm. BSA and D-ribose mixture incubated for 21 days showed drastic 
reduction of the featured helical pattern, indicating that BSA has lost α-helix 
structures during glycation due to the formation of AGEs and the consequent 
protein conformation change.  
In experiment A (figure 3), profile b, c and d are designated to BSA 
glycated by D-ribose in the presence of 20 nm, 2 nm and 5 nm GNP solution 
respectively. Similar to earlier observations from UV spectrum scan, reaction 
mixture with 5 nm GNP retained most of the α-helical content of BSA, 
producing a spectrum profile most similar to the profile of natural BSA which 
has not been glycated by reducing sugar. BSA treated by 2 nm and 20 nm 
GNPs also revealed decreases in the loss of secondary structure comparing 
to control BSA which was glycated without GNP. CD spectrums for samples 
in experiment A revealed that reaction mixture with 5 nm retained the most 
helical structure followed by 2 nm sample then 20 nm. In contrast, CD 
profiles for experiment B seen in figure 4 showed that all three sizes of 
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nanoparticle exhibited similar anti-glycation ability, producing CD spectrum 
almost superimposable to each other. 
Figure 5 and figure 6 display the respective HPLC elution profiles of 
reaction mixtures in experiment A incubated at 37 °C for 21 days. Both UV 
and fluorescence signals were monitored in the HPLC profile. Profile 5a 
shows the HPLC-UV elution data of solutions containing BSA alone (blank). 
BSA alone eluted as one prominent peak with a retention time (Rt) of 15.79 
min. BSA glycated by D-ribose without the treatment of GNPs (profile 5b) 
yielded three AGE products by HPLC labeled as peak 1, 2 and 4. Of the 
bands corresponding to the AGE products, peak 1 and 2 were not well 
separated and eluted with a retention time of 2.25 min while peak three 
eluted at 5.21 min. Integration of the band areas (data shown in table II) 
revealed that without the treatment of GNPs, glycated BSA produced three 
AGEs adducts with the first two yielding a total peak area of 258.62 and the 
third of 12.39 respectively. In contrast, profiles of BSA glycated in the 
presence of GNPs (5c, 5d and 5e) revealed a disappearance of peak 4, 
indicating that less AGE species was formed in the presence of GNPs. 
Moreover, the peak areas of peak 1 and 2 in profiles 5c, 5d and 5e were 
noticeable reduced comparing to profile b, yielding a total AGE peak 
intensity of 88.78, 82.10 and 87.23 respectively. Peak 3 in profile b, c d and e 
indicated BSA with sugar addicts, yielding a broad HPLC band comparing to 
that of native BSA. The peak area of this bank also demonstrated the extent 
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of glycation since BSA with more sugar addicts would produce a broader 
band resulting in an increase in peak intensity. BSA glycated by D-ribose 
without GNP, again, yield a band with the highest peak area of 316.67 
indicating the production of glycated BSA with most sugar addicts. BSA 
incubated with different sizes of GNPs all revealed a decrease in the peak 
area, and 5 nm GNP exhibited the most reduction in BSA glycation with peak 
intensity of 138.39, followed by 2 nm GNP (peak area= 151.95) and 5 nm 
GNP (peak area= 173.65).  
To determine the number of sugar addicts on protein forming by 
glycation, we used MALDI-TOF to compare the mass shift of glycated BSA 
with native BSA. Figure 7 to 11 are MALDI spectrum of reaction mixtures in 
experiment A: native BSA (fig. 7), BSA incubated with D-ribose (fig. 8), BSA 
and D-ribose mixture with 2 nm GNP (fig. 9), BSA and D-ribose mixture with 
5 nm GNP (fig. 10), BSA and D-ribose mixture with 20 nm GNP (fig. 11). In 
table III we summarized the peak m/z value in each MALDI profile and the 
mass shift comparing to native BSA. Since the increase in m/z value was 
mainly due to the addict of D-ribose molecules to the protein, the 
approximate number of D-ribose adducts on glycated BSA in each 
incubation mixture can be also calculated based on the shift in m/z value 
(shown in table III). A greater number of sugar addicts on protein revealed a 
higher extent of glycation, resulting in a more rapid and an enhanced 
formation of AGEs. A close scrutiny of the table confirmed the earlier 
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observations that the extent glycation of BSA was reduced by adding GNPs 
into the solution. Mixture containing BSA and D-ribose alone showed the 
highest shift in protein m/z value and 80 sugar molecules were estimated to 
bond with native protein after 21 days incubation. The number of sugar 
addicts was reduced considerably in reaction mixtures containing BSA and 
D-ribose with 2 nm, 5 nm or 20 nm GNPs. 5 nm GNP solution which 
exhibited the highest total nanoparticle surface area yielded the least shift in 
m/z value, followed by 2 nm GNPs and then 20 nm. This order, again 
corresponded to the order of total nanoparticle surface areas in each 
solution (5nm>2nm>20nm), confirming that GNP’s anti-glycation ability is 
directly correlated to the total nanoparticle surface area in each solution. 
GNP solution with enhanced total surface area exhibited a higher inhibitory 
effect against the formation of AGEs. This anti-glycation property of AGEs 
was reduced by decreasing the nanoparticle numbers in solution which 
resulted in a decrease of total particle surface area.  
4. Discussion 
The non-enzymatic glycation of protein by reducing sugars causes the 
irreversible formation of AGEs, a heterogeneous group of compounds 
accumulating in vivo over times. The built up of AGEs has been implicated 
to be related to the pathology of several long term diseases including 
diabetes and AD. Thus the search for anti-glycation agents is an important 
clinical issue since an increasing amount of AGE modified proteins have 
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been detected during the development of such diseases. Unfortunately, 
though several potential inhibitors against the formation of AGEs have been 
discovered and proposed, no promising anti-glycation drug has been 
applied clinically. Since glycation is a complicated process involving multiple 
targets and bio-pathways, the invention of inhibitors against such biological 
event is challenging. In this study, we evaluated the effect of gold 
nanoparticles on the formation of AGEs using BSA glycated by D-ribose as 
model reaction. The anti-glycation efficiency of GNPs with different particle 
diameters ranging from 2 nm to 200 nm was also compared.  
Our studies showed that spherical GNPs with particle diameter larger 
than 20 nm (50 nm, 100 nm and 200 nm) aggregated with BSA after two to 
three days incubation, forming insoluble precipitants in phosphate buffer. 
However, 2 nm, 5 nm and 20 nm GNPs retained their nanoparticle properties 
without aggregating with BSA during incubation. Moreover, BSA-ribose 
reaction mixture treated with 2 nm, 5nm or 20 nm GNP all showed a reduced 
glycation level comparing to BSA incubated with D-ribose alone. UV 
spectrum revealed that under the treatment of GNPs, less aromatic AGEs 
were formed during the incubation of BSA with D-ribose. This result was 
confirmed by HPLC elution profiles that less AGE peaks and lower peak 
intensities were detected in reaction mixtures containing GNPs. It was also 
shown that GNP retained the secondary structure of BSA and prevented the 
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conformational change of protein, a finding which was demonstrated by CD 
spectrum.  
The other important finding of this study was the correlation between 
GNP’s anti-glycation efficiency and the total nanoparticle surface area in the 
solution. GNP’s inhibitory effect against the formation of AGEs could be 
enhanced by increasing the total GNP particle surface areas in solution. This 
can be achieved by increasing the total nanoparticle concentration or 
increasing the nanoparticle sizes. It should be noted that larger size GNP or 
saturated GNP solution tends to conjugate with protein and precipitates out. 
Thus it is important to keep the particle size and concentration within a range 
which GNPs still retain their nanoparticle properties without aggregating with 
protein during glycation. In our study, we found that 5 nm GNPs with an Au 
mass concentration of 0.05 mg/ml exhibited the most anti-glycation ability 
while stayed homogenously during the entire incubation process.  
The mechanism of GNP’s inhibitory effect against the formation of 
AGEs is still under investigation. We proposed that GNPs competitively bind 
to the potent glycation sites on BSA, preventing their further modification by 
glycation. There is a strong implication that amino acid residues are able to 
covalently bond to the gold atoms on the surface of nanoparticle through 
Au-S or Au-NH2 bonds. Such binding not only stabilizes nanoparticle from 
conjugation, but also protects free amino groups such as lysine from 
glycation. Furthermore, GNP could possibly bind to the glycation 
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intermediates of protein and prevent the formation of reactive dicarbonyl 
compounds. 
In the specific case of our study, GNP with a higher surface area 
exhibited better inhibitory ability against glycation, probably due to the 
increase in available binding area on GNP surface to protein’s potential 
glycation sites. As GNP is highly biocompatible and water soluble, an insight 
of its anti-glycation effect and its inhibition mechanism on the formation of 
AGEs might lead to a novel therapeutic application of GNP on reducing AGE 
related complications. 
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Figure 1. UV absorbance spectrum of reaction mixtures in experiment A. 
Each group contained 35 mg/ml BSA and 20 mM D-ribose incubated with 
and without different sizes of GNP (2 nm, 5 nm and 20 nm) at 37 °C for 21 
days. The Au mass concentration was adjusted to 0.05 mg/ml in solutions 
containing GNP resulting in different total nanoparticle surface area (refer to 
table I). The spectrum is ranging from 250 nm to 400 nm with glycation 
products absorbed most at 280 nm. All data points represent the averages of 
three replicate measurements.  
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Figure 2. UV absorbance spectrum of reaction mixtures in experiment B. 
Each group contained 35 mg/ml BSA and 20 mM D-ribose incubated with or 
without different sizes of GNP (2 nm, 5 nm and 20 nm) at 37 °C for 21 days. 
The total nanoparticle surface area in each solution was adjusted to the 
same value (refer to table I). The spectrum is ranging from 250 nm to 400 nm 
with glycation products absorbed most at 280 nm. All data points represent 
the averages of three replicate measurements.  
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Figure 3. CD profiles of reaction mixtures in experiment A: (A) 35 mg/ml BSA 
and 20 mM D-ribose without GNP, (B) 35 mg/ml BSA and 20 mM D-ribose 
with 20 nm GNP, (C) 35 mg/ml BSA and 20 mM D-ribose with 2 nm GNP, (D) 
35 mg/ml BSA and 20 mM D-ribose with 5 nm GNP and (E) 35 mg/ml BSA 
alone at 37 °C for 21 days. BSA concentration was diluted to 0.5 mg/ml with 
deionized water before analysis. Repeat scan revealed no significant 
difference in the spectra.  
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Figure 4. CD profiles of reaction mixtures in experiment B: (A) 35 mg/ml BSA 
and 20 mM D-ribose without GNP, (B) 35 mg/ml BSA and 20 mM D-ribose 
with 20 nm GNP, (C) 35 mg/ml BSA and 20 mM D-ribose with 5 nm GNP, (D) 
35 mg/ml BSA and 20 mM D-ribose with 2 nm GNP and (E) 35 mg/ml BSA 
alone at 37 °C for 21 days. BSA concentration was diluted to 0.5 mg/ml with 
deionized water before analysis. Repeat scan revealed no significant 
difference in the spectra.  
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Figure 5. HPLC-UV elution profile for reactions in experiment A. 35 mg/ml 
BSA alone served as blank solution (a). 35 mg/ml BSA incubated with 20 
mM D-ribose without GNP served as control solution (b). Profiles for BSA 
glycated at the presence of different sizes of GNP are shown in c (20 nm), d 
(5 nm) and e (2 nm). All reaction mixtures were incubated in dark at 37 °C for 
21 days.  
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Figure 6. HPLC-fluorescence elution profile for reaction mixtures in 
experiment A. 35 mg/ml BSA alone served as blank solution (a). 35 mg/ml 
BSA incubated with 20 mM D-ribose without GNP served as control solution 
(b). Profiles for BSA glycated at the presence of different sizes of GNP are 
shown in c (20 nm), d (5 nm) and e (2 nm). All reaction mixtures were 
incubated in dark at 37 °C for 21 days.  
.  
Peak 1 
Peak 2 
123 
 
 
 
Figure 7. MALDI-TOF profile of reaction mixtures containing 35 mg/ml BSA 
incubated in dark at 37 °C for 21 days. The spectrum peak indicates to 
double charge intact BSA. The maximum peak m/z value was found at 
33100.  
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Figure 8. MALDI-TOF profile of reaction mixture in experiment A which 
contained  35 mg/ml BSA glycated by 20 mM D-ribose in dark at 37 °C for 
21 days. The spectrum peak indicates to double charge glycated BSA. The 
maximum peak m/z value was found at 39100.  
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Figure 9. MALDI-TOF profile of reaction mixture in experiment A which 
contained 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 2 
nm GNP with Au mass concentration of 0.05 mg/ml. The reaction took place 
in dark at 37 °C for 21 days. The spectrum peak indicates to double charge 
glycated BSA. The maximum peak m/z value was found at 37170. 
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Figure 10. MALDI-TOF profile of reaction mixture in experiment A which 
contained 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 5 
nm GNP with Au mass concentration of 0.05 mg/ml. The reaction took place 
in dark at 37 °C for 21 days. The spectrum peak indicates to double charge 
glycated BSA. The maximum peak m/z value was found at 36980. 
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Figure 11. MALDI-TOF profile of reaction mixture in experiment A which 
contained 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 20 
nm GNP with Au mass concentration of 0.05 mg/ml. The reaction took place 
in dark at 37 °C for 21 days. The spectrum peak indicates to double charge 
glycated BSA. The maximum peak m/z value was found at 37780. 
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Tables: 
 
Table I. 
Particle Size and Surface Area of 2nm, 5nm, 20nm Gold Colloid Water 
Solution in Experiment A and B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Particle Size 
(nm) 
Particle/ml 
Au Mass 
Concentration 
(mg/ml) 
Single Particle 
Surface Area 
(nm
2
) 
Total Particle 
Surface Area/ml 
(nm
2
/ml) 
A 
2 nm 1.5 X 10
14
 0.05 50 7.54 X 10
15
 
5 nm 5.0 X 10
13
 0.05 314 15.7 X 10
15
 
20 nm 7.0 X 10
11
 0.05 5024 3.52 X 10
15
 
B 
2 nm 7.0 X 10
13
 0.02 50 3.52 X 10
15
 
5 nm 1.0 X 10
13
 0.01 314 3.52 X 10
15
 
20 nm 7.0 X 10
11
 0.05 5024 3.52 X 10
15
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Table II.  
HPLC Peak Areas of BSA AGEs generated under incubation condition 
with or without different sizes of GNP in experiment A 
 
 UV Absorbance at 280nm 
Fluorescence Intensity 
(Excitation: 340nm Emission: 420nm) 
BSA+D-Ribose 
with 2nm GNP 
Peak1 and 2 
 
87.227 
Peak 3 
 
151.948 
Peak 1 
 
22.099 
Peak2 
 
374.429 
BSA+D-Ribose 
with 5nm GNP 
Peak1 and 2 
 
82.097 
Peak 3 
 
138.390 
Peak 1 
 
12.347 
Peak 2 
 
346.101 
BSA+D-Ribose 
with 20nm GNP 
Peak1 and 2 
 
88.782 
Peak 3 
 
173.654 
Peak 1 
 
44.230 
Peak 2 
 
435.874 
BSA+D-Ribose 
without GNP 
Peak1 and 2 
 
258.626 
Peak 3 
 
316.672 
Peak 1 
 
144.484 
Peak 2 
 
502.327 
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Table III. 
Mass Shift of BSA glycated by D-ribose with or without the presence of 
GNP in experiment A 
 
 
Peak m/z value 
(double charge) 
Glycated BSA shifted 
m/z 
(double charge) 
Approximate number of 
D-ribose adducts 
BSA Blank 33100 0 0 
BSA +D-Ribose 39100 6000 80 
BSA+D-Ribose+ 2nm 
GNP 
37170 4070 54 
BSA+D-Ribose+ 5nm 
GNP 
36980 3800 50 
BSA+D-Ribose+ 20nm 
GNP 
37780 4680 62 
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Abstract: 
 
Non-enzymatic glycation of human serum albumin (HSA) is a major 
contributor to the pathology of diabetes. The final products of this reaction 
are a polymorphic group of compounds collectively referred to as Advanced 
Glycation Endproducts (AGEs). Exposure to ultraviolet C (UVC) irradiation is 
known to perturb protein structure and generate reactive oxygen species 
(ROS) such as hydrogen peroxides, which might eventually accelerate 
protein glycation and enhance the formation of AGEs. The objective of this 
study was to evaluate the effect of UVC irradiation on the glycation level of 
human serum albumin and the formation of carboxymethyl lysine (CML), a 
well characterized AGE which is used  as  a  biomarker  of  oxidatively  
damaged tissues  in  vivo. A combination of several analytical methods 
including UV spectrometry, HPLC and MALDI-TOF were used to study the 
glycation level of HSA at 37 °C under neutral pH in the presence of 
D-glucose in vitro. Compared to the untreated HSA, UVC exposed HSA 
showed a more rapid increase in absorbance intensity at 280 nm over time, 
as well as enhanced peak areas of AGEs in the HPLC elution profile. In 
MALDI-TOF spectrum, more D-glucose adducts were found on UVC treated 
HSA, generating a higher mass shift of protein. We also quantified the 
amount of CML using enzyme-linked immunosorbent assay technique with a 
monoclonal antibody which recognizes CML. Comparing to control samples 
in the dark, reactions exposure to UVC radiation produced about double 
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amount of CML within 48 hours of incubation. In conclusion, exposure to 
UVC radiation accelerates the glycation level of HSA and promotes the 
formation of AGEs, which may be stimulated by the generation of ROS by 
UV radiation. This study warrants further investigation as there have been 
few reports on the correlation between the UV radiation of proteins and their 
enhanced glycation by a reducing sugar.   
 
Key words: HSA, CML, glycation, UVC, ROS 
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1. Introduction 
Human serum albumin (HSA) constitutes almost half of the protein 
content in the plasma of normal healthy individuals [1]. As one of the major 
circulating protein in blood, HSA is the most abundant protein and utilizes a 
wide variety of physiological functions due to the flexibility of its structure [2]. 
First of all, albumin has a comparatively low molecular weight of 66 KDa 
comparing to other globulins in the plasma system. This property makes the 
protein a key element in maintaining the osmotic pressure needed for 
proper distribution of body fluids between intravascular compartments and 
body tissues [3]. HSA also functions as a carrier protein for small size 
metabolites such as hydrophobic steroid hormones, ions and fatty acids. 
The binding sites which allow the affinity for these metabolites are 
distributed widely on all three domains of the protein. As a result, albumin is 
also involved in the pharmacokinetics of many therapeutic drugs that can be 
bound to the protein [4, 5]. In addition, HSA represents the predominant 
antioxidant in plasma, a body compartment continuously exposed to high 
oxidative stress [6, 7]. Previous study has shown that more than 70% of the 
free radical-trapping activity of serum was due to HSA [6]. 
In normal conditions, HSA has a long half-life time of about 21 days and 
a high plasmatic concentration between 35 to 50 mg/ml. Being constantly 
exposed to numerous metabolites, albumin is highly sensitive to the 
structural modification by these molecules. In particularly, non-enzymatic 
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glycation is among the major mechanisms which contribute to the alteration 
of HSA’s functions. Glycation is a non-enzymatic process that involves a 
series of steps initiated with a condensation reaction between the aldehyde 
group of a reducing sugar and the free amino group of a protein, resulting in 
the formation of an unstable aldimine, also known as the Schiff base. This 
intermediate then undergoes Amadori rearrangement and converts to a 
more stable ketoamine structure referred to as Amadori products. Late stage 
of glycation involves irreversible modification of these early stage glycation 
intermediates such as dehydration, cyclization, oxidation, and 
rearrangement to form a polymorphic group of compounds called advanced 
glycation endproducts (AGEs) [8-10]. The accumulation of AGEs plays a 
significant role in the pathogenesis of diabetic complications.  
Glycated albumin accounts for about 80% of the circulating glycated 
protein [11]. In vivo, the proportion of glycated albumin in healthy persons is 
in the range of between 1% and 10% [2]. In the case of diabetes mellitus, the 
proportion of glycation HSA may increase two to three fold and even reach to 
90% for severe diabetic patients with poor diabetic control [12, 13]. 
Glycation-induced modiﬁcations have a determinant impact on HSA’s 
biological functional properties such as its antioxidant property and 
metabolites binding capacity. In addition, glycation is accompanied by the 
production of AGEs, which triggers the release of pro-inflammatory 
molecules and free radicals, inducing oxidative cellular dysfunction. 
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The glycation level of HSA can be up-graded by several factors 
including genetic deficiency, high calories diet and environmental factors. 
UV light is electromagnetic radiation with a wavelength in the range of 100 
nm to 400 nm. UV radiation is classified into three types or bands—UVA 
(400-315 nm), UVB (315-280 nm), and UVC (280-100 nm). Exposure to 
ultraviolet (UV) irradiation is known to perturb protein structure and generate 
reactive oxygen species (ROS) [14, 15]. Solar UVC is absorbed by ozone in 
the stratosphere and the biological effect on human beings from natural 
sources is limited. However, with increasing use of man-made UVC radiation 
such as germicidal application and light therapy for wound healing, there is a 
growing concern about the biological effect of UVC. Previously study has 
shown that UVC irradiation could disturb structural stability of HSA and 
cause conformational rearrangement and aggregation of the protein [16]. 
The production of ROS was also found to be stimulated by UVC irradiation in 
vivo [17].  
ROS play a significant role in the mechanism of protein glycation. The 
free radicals are not only the product of glycation, but can also accelerate the 
reaction rate and enhance the formation of AGEs. This suggests that UVC 
radiation might eventually promote protein glycation by disturbing structural 
stability of HSA and producing ROS. The objective of this study was to 
evaluate the effect of UVC irradiation on the glycation level of human serum 
albumin when D-glucose was used as model glycator. The formation of 
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carboxymethyl lysine (CML), a well characterized AGE which is used as a 
biomarker of oxidatively damaged tissues was also measured. A 
combination of several analytical methods including UV spectrometry, HPLC, 
ELISA and MALDI-TOF were used to study the glycation level of HSA at 
37 °C under neutral pH in the presence of D-glucose in vitro. 
 
6 Materials and methods 
6.1 Chemicals and supplies 
Fatty acid free albumin from human serum (HSA) and analytical grade 
D-glucose were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, 
USA). Disposable UV-transparent cuvettes (12.5 mm X12.5 mm X 36 mm) 
and HPLC analytical grade solvents were obtained from Thermo Fisher 
Scientific (Rockford, IL, USA). Ziptip pipette tips with C4 resin and 0.22 µm 
filter unit were purchased form EMD Millipore Co. (Billerica, MA, USA). 
Photometric Enzyme-Linked Immunosorbent Assay (ELISA) kit for the 
quantitative determination of Carboxymethyl Lysine (CML) was purchased 
from Neo Bio Lab (Cambridge, MA, USA). Unless otherwise indicated, all 
other reagents of analytical grade were purchased from Sigma-Aldrich 
Chemical Co. (St. Louis, MO, USA).  
6.2 Sample preparation and UVC exposition 
Stock solutions of HSA (105 mg/ml) and D-glucose (100 mM) were 
prepared in 0.1 M phosphate buffer, pH 7.2. Blank solutions included 35 
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mg/ml HSA alone or 20 mM D-glucose alone. Controls included 35 mg/ml 
BSA incubated with 20 mM D-glucose incubated in dark without any 
exposure to UVC radiation. The concentration of HSA was adjusted to 35 
mg/ml because this is the reported serum albumin concentration in health 
human individuals. The concentration of D-glucose was adjusted to 20 mM, 
the concentration reported to be the blood sugar content under diabetic 
condition. Two sets of studies were conducted designated as experiment A 
and experiment B.  
In experiment A, 35 mg/ml HSA incubated with 20 mM D-glucose in 0.1 
M phosphate buffer at 37 °C, pH 7.2 for up to 14 days. Reaction mixture 
incubated in dark without any exposure to UVC radiation was serving as 
control solution. Experiment group was exposed to UVC light with a peak 
wavelength at 254 nm. The UVC radiation was produced by a 30 watts 
low-pressure vapor discharge lamp.  
In experiment B, HSA was exposed to UVC light for 24 hours before the 
glycation agent was added into the solution. In control group, 35 mg/ml HSA 
was incubated in dark at 37 °C for 24 hours and then mixed with 20 mM 
D-glucose. In comparison, experiment solution was prepared by first 
exposing 35 mg/ml HSA under UVC light with a peak wavelength at 254 nm 
for 24 hours, then mixing with 20 mM D-glucose. Both control and 
experiment samples were then incubate in dark at 37 °C for up to 96 hours. 
After incubation, all reaction mixtures were placed at -20 °C until analyzed. 
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Prior analysis, all samples were unfrozen, ultra-centrifuged at 5X103 rpm for 
15 min and the supernates were further purified by ZipTip pipette with C4 
resin. 
2.3 UV spectroscopy 
UV readings were obtained at a wavelength of 280 nm with an 
UltroSpec 2100 instrument (Biochrom Ltd, Cambridge, UK). The above 
wavelength was determined optimal for detecting HSA AGEs by spectrum 
scan ranging from 200 nm to 400 nm. All samples were diluted 20 fold before 
analysis and all readings were obtained in thermostatically controlled 
cuvettes that were maintained at 25±1 °C. All values are the average of 
triplicate measurements.  
2.4 High-performance liquid chromatography 
Each HPLC run was performed in triplicate using a Hewlett Packard 
1050 system (Waldbronn, Germany) equipped with a low-pressure gradient 
pump, a four-channel degasser, a sequential auto sampler, a high sensitivity 
diode-array detector (190–800 nm) and a programmable fluorescence 
detector (HP 1046A). The HPLC system was operated with the ChemStation 
System from Agilent Technologies (Santa Clara, CA, USA) with the same 
software used also for data analysis.  AGE species were separated on a 
Shodex (New York, NY, USA) RSpak C18 reverse phase HPLC column (5 
μm×4.6 mm×150 mm) with 415 Å pore size. Mobile phase A consisted of 0.1% 
trifluoroacetic acid (TFA) in water and mobile phase B consisted of 0.1% 
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TFA in ACN. A linear gradient from 20% to 60% of mobile phase B was 
applied in 20 minutes at a constant flow rate of 1.0 ml/min. Prior to HPLC 
analysis, all solvents were degassed and sonicated for 15 min. All samples 
were filtered with a 0.22 μm membrane, degassed and centrifuged.   
2.5  ELISA with anti-CML AGE antibodies 
ELISA assay was performed according to the standard procedure 
provided by Neo Bio lab form where the ELISA assay kit (Catalog Number: 
PC0780) was obtained. Each sample was first diluted 10 times to 100 µl and 
then added to the labeled wells in the supplied microtiter plate. Then 50 µl of 
conjugate solution was added in each well and the plate was covered and 
incubated for 1 hour at 37 °C. Each well was washed for 5 times with 
300-400 µl wash solution followed by the addition of 50 µl substrate A to 
each well and then 50 µl substrate B. The plate was again covered and put 
into incubation for 15 minutes at room temperature. Finally, 50 ul of stop 
solution was added to each well and the optical density (O.D.) for each 
sample was immediately determined at 450 nm using a Spectra Max M2 
spectrometer (Molecular Devices, Sunnyvale, CA). Each experiment 
solution was run in duplicate and the values were averaged.  
2.6 Preparation and analysis of intact HSA by MALDI-TOF MS 
All samples were purified with C4 ZipTips and analyzed on a Bruker 
Autoflex MALDI–TOF (time-of-flight) mass spectrometer (Bruker Daltonics, 
Billerica, MA, USA). Prior to analysis, the protein samples (0.6 μl) were 
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mixed with a 50% aqueous acetonitrile solution (0.6 μl) of saturated sinapinic 
acid containing 0.05% trifluoroacetic acid (TFA) as matrix, spotted onto a 
stainless steel sample plate, and allowed to air dry. Spectra were acquired in 
linear TOF mode with a 550 ns delay in the m/z range from 20,000 to 80,000. 
Each spectrum was the sum of 500 single laser shots randomized over 10 
positions within the same spot (500/50). Analysis of data was performed 
using FlexAnalysis and ClinProTools (Bruker Daltonics). 
 
3 Results 
3.1 Detection of aromatic AGEs by UV spectrometry 
    Tables I shows the UV absorption readings of incubation mixtures 
containing 35 mg/ml HSA with 20 mM D-glucose (hereinafter referred to as 
“HSA-glc”) in both experiment A and B. In experiment A, samples were 
collected at different time points (0, 1, 2, 4 and 7 days of incubation 
respectively). In both control sample which was incubated in dark and 
experimental sample which was exposed to constant UVC radiation, HSA 
was found to form AGEs and the highest levels of glycation were achieved 
when HSA reacted with D-glucose for 7 days. It should be noted that a 
severe protein crosslinking was observed in UV exposed sample after 7 
days incubation. HSA denatured and precipitated out of phosphate buffer 
due to protein conjugation. As a result, only samples collected within the first 
7 days of reaction were analyzed afterwards. A considerable difference in 
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UV intensities between control sample and UVC treated sample revealed 
that exposure to UVC radiation enhanced the glycation level of HSA. The 
formation of aromatic AGEs which exhibited a UV absorbance at 280 nm 
was boosted by UVC treatment, producing a UV intensity value (λ280=1.172) 
almost double as the untreated HSA-glc mixture (λ280=0.623) after 7 days 
incubation. No increases were observed in the UV absorbance of blanks 
containing HSA alone. Similarly, no increases in the UV absorbance of 
control tubes containing freshly added HSA with D-glucose were noted. In 
experiment B, HSA was pre-incubated under the exposure of UVC radiation 
before D-glucose was added to the solution. A close scrutiny of the UV 
values in table I revealed that comparing to control, the rate and extent of 
glycation in UVC treated sample were much higher even at the initially stage 
of the reaction after 24 hours incubation, yielding an intensity value 
(λ280=1.322) almost four times higher than the untreated solution 
(λ280=0.091). Similar to experiment A, HSA started to form cross-linked 
structures and precipitated out of the mixture after 96 hours incubation. As a 
result, only samples collected within the first 96 hours of reaction in 
experiment B were analyzed afterwards. The UV readings obtained at 280 
nm revealed two important findings: 1) UVC radiation enhanced the 
formation of aromatic AGEs of HSA, which was found to be responsible for 
the increased UV intensity at 280 nm; 2) HSA exposed to UVC radiation was 
more prone to be glycated by reducing sugar. This finding suggested that 
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UVC treatment might cause conformational restructuring of HSA, making the 
protein more susceptible to glycation. 
3.2  Quantification of AGEs by HPLC  
The extent of HSA glycation under the treatment of UVC radiation in 
both experiment A and B was determined by HPLC. Figure 1 shows the 
HPLC elution profile of blank solution of HSA alone and control solutions of 
HSA freshly added to D-glucose. Protein alone eluted as one prominent 
peak with a retention time (Rt) of 14.02 min. Under the same separation 
conditions, freshly mixed solutions of HSA with D-glucose also yielded one 
discrete peak coincident in location with that of HSA (Rt=14.02 min). This 
control showed that immediate mixing of the sugar with HSA had no effect on 
the elution profile of HSA itself; nor did it immediately cause the formation of 
AGEs. 
Figure 2 and figure 3 show the HPLC elution profiles of HSA-glc mixture 
incubated in dark (figure 2) or incubated under the exposure to UVC 
radiation (figure 3) for 2 days in experiment A. A series of new peaks that 
emerged represent the formation of several AGE species in both solutions. 
According to the peak area intensities of these glycation products numbered 
peak 1 (Rt=1.87 min), peak 2 (Rt=3.15 min) and peak 3 (5.10 min), 
experimental sample under UVC radiation yielded AGE peaks with higher 
band areas comparing to that of control solution incubated in dark (data 
shown in Table II). Meanwhile, the peak area of band eluted at 14.02 min 
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which represented unglycated HSA had a lower value than HSA peak in 
control mixture; indicating HSA had been modified by D-glucose more 
intensively to form AGEs when treated by UVC. HPLC Elution profiles of 
HSA-glc mixture incubated for 7 days were shown in figure 4 (control 
solution incubated in dark) and figure 5 (experimental solution incubated 
under UVC radiation). Again, three AGE species were observed in both 
profiles. However, the amount of unglycated HSA was drastically decreased 
comparing to that of control, yielding a peak intensity of only 715.3. In the 
meanwhile, the peak area of AGE eluted as peak number 1 in UV treated 
sample was much higher than that of the solution incubated in dark, 
revealing a higher glycation level.  
Figure 8 and 9 show the HPLC elution profiles of reaction mixtures in 
experiment B after 48 hours incubation. Incubations of UVC-treated HSA 
with D-glucose yielded four additional peaks numbered 1, 2, 3, and 4 with 
retention times of 1.71 min, 1.87 min, 3.14 min and 5.08 min respectively 
(seen in figure 9). Whereas profile of untreated HSA incubated with 
D-glucose for 48 hours indicated the formation of only three AGE species 
formed, a result indicated that more AGE species were formed when HSA 
was pre-treated with UVC radiation for 24 hours. Moreover, the peak 
intensity of AGE species in UVC treated solution was higher than the value 
of untreated control sample, verifying that exposure to UVC radiation made 
HSA more susceptible to glycation by reducing sugar.  
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3.3  The detection of CML by ELISA 
CML is an AGE resulted from oxidative stress and chemical glycation. 
CML adducts was found accumulated with aging and over produced in 
several diabetic related complications. CML-modified proteins are 
recognized by the receptor RAGE which is expressed on a variety of cells. 
This process could initiate the expression of ROS and induce oxidative 
stress. The formations of CML in HSA-glc mixtures in both experiment A and 
B were evaluated by ELISA assy. Higher levels of CML leaded to increased 
CML-antibody conjugate binding and greater OD signal at 450 nm. Figure 10 
shows the OD intensities of reaction mixtures in experiment A including a) 35 
mg blank HSA, b) HSA-glc incubated in dark and c) HSA-glc incubated 
under UVC radiation. The increased in OD value over time revealed the 
formation of CML in both mixture b and c over time. No OD absorbance at 
450 nm was observed when HSA was incubated along without any glycation 
agent. Comparing to sample incubated in dark, UVC treated solution 
produced a much higher amount of CML and the highest CML level was 
observed in HSA-glc mixture incubated under UVC radiation for 7 days. In 
experiment B, HSA pre-treated by UVC radiation yielded more CML 
comparing to untreated HSA (showing in figure 11). The difference in CML 
levels between control solution and UVC exposed sample started to be 
observed at the very early stage of glycation after only 12 hours of incubation. 
After 48 hours, UVC treated HSA produced about double amount of CML 
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comparing to control solution, an observation confirming our earlier 
conclusion base on UV spectrometry and HPLC elution profile.  
3.4  Measurement of HSA mass shift by MALDI-TOF 
To determine the number of sugar addicts on HSA forming by glycation, 
we used MALDI-TOF to quantify the mass shift of glycated HSA comparing 
to unglycated BSA. Since the increase in m/z value was mainly due to the 
addict of D-glucose molecules to the protein, the approximate number of 
sugar adducts on glycated HSA in each incubation mixture can be calculated 
based on the shift in m/z value (shown in table III). A greater number of sugar 
addicts on protein revealed a higher extent of glycation, resulting in an 
enhanced formation of AGEs. It should be noted that each MALDI spectra 
shown in figure 12 to figure 18 reflected the double charged albumin 
molecule which gave a better spectrum peak in each profile. As a result, the 
actual mass value for glycated HSA should be doubled by the m/z value 
obtained in MALDI spectrum. 
A close scrutiny of the table confirmed the earlier observations that the 
extent of HSA was enhanced by exposing sample to UVC radiation. Solution 
containing HSA alone showed m/z value of 33000 Da in double charged 
form, resulting in a protein mass of 66000 Da which is closed to the reported 
HSA molecule weight. Based on the mass shift, the glycation levels of 
reaction mixtures in experiment A were not very considerable after 2 days 
incubation. In solution incubated in dark, one D-glucose addict was found on 
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HSA after 2 days reaction and two sugar molecules were found to addict on 
HSA in UVC treated sample. The difference was enhanced by prolonging the 
incubation time to 7 days. In samples incubated for 7 days, we noticed a 
mass shift of 740 in solution exposed to UVC radiation, which equals to 8 
D-glucose addicts, whereas only 3 sugar molecules were found to addict on 
HSA in mixture incubated in dark. This observation again corresponded to 
our early conclusion that UVC irradiation enhanced the degree of glycation.  
Moreover, HSA pre-incubated under UVC radiation for 24 hours in 
experiment B yielded mass shift of 290 after 48 hours incubation, which 
equals to 3 D-glucose addicts on HSA. Interestingly, this number is closed to 
the mass shift produced by HSA-glc mixture incubated in dark for 7 days, 
which suggested that the exposure to UVC not only enhanced the glycation 
level, but also increased the reaction rate.  
 
4. Conclusion 
The non-enzymatic glycation of HSA has been found to play a major role 
in human physiology. The reactive carbonyl groups of reducing sugars 
condensed with the amino groups of certain amino acid residues such as 
lysine and arginine on HSA and form Amadori products that can rearrange to 
form AGEs after a variety of chemical reactions. Accumulation of AGEs has 
been reported to account for many of the chronic complications including 
diabetes and Alzheimer’s disease.  
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Recently, there has been an increasing interest on the physiological 
effect of UVC radiation since they are readily absorbed by DNA and are 
highly genotoxic [19]. The biological effects of ultraviolet radiation (UV) 
include DNA damage, mutagenesis, cellular aging, and carcinogenesis. 
These effects are in part mediated by reactive oxygen species (ROS), the 
production of which is stimulated by UV irradiation of cells and tissues [16, 
18]. Since the production of ROS also enhanced the glycation level in 
biological system, current study made an effort to evaluate the influence of 
UVC radiation on the formation of AGEs when physiological concentration of 
HSA was glycated by D-glucose in-vitro.   
A combination of several analytical methods including UV spectrometry, 
HPLC and MALDI-TOF revealed that UVC radiation enhanced the glycation 
level of HSA even at the early stage of the reaction. Moreover, the glycation 
rate was also boosted when the reaction took place under UVC exposure. 
HSA started to form noticeable cross-link structures after a few days 
treatment with UVC, denaturized, and precipitated out from the reaction 
system. HSA pre-incubated under UVC radiation was more susceptible to 
glycation by reducing sugar comparing to untreated HSA. Although the 
detailed mechanism of this phenomenon is still under elucidation, it might be 
related to the alteration in HSA’s conformational structure when the protein is 
exposed to UVC radiation. 
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In this study we also quantified the production of CML from HSA 
glycation using ELISA immune assay. The major source of CML during 
protein glycation is oxidative degradation of Amadori intermediate and ROS 
was found to accelerate the formation of CML. We observed a considerable 
increase in CML production when the protein was glycated under UVC 
radiation; a finding suggested that UVC radiation promoted the formation of 
ROS, which could then stimulate oxidative degradation of Amadori addicts to 
form AGEs.  
At present, there is little information on the biological effect of short UV 
wavelength, and there is practically no data on glycation of HSA under the 
influence of UVC radiation. UVC radiation was found to enhance the 
glycation rate and promote the formation of HSA AGEs. The high energy UV 
radiation was also suspected to perturb protein structure; making protein 
more susceptible to glycation. As a result, more attention on the safe usage 
of UVC light should be addressed because the negative biological effect of 
high energy, short wavelength UV may not only be related to their genotoxic 
but may also be caused by their ability to enhanced protein glycation. 
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Figure 1. HPLC-UV elution profile of 35 mg/ml HSA alone in 0.1 M 
phosphate buffer, pH 7.2 serving as blank solution. HSA eluted at 14.02 
minute, producing a single peak with a total peak area of 1402.6.   
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Figure 2. HPLC-UV elution profile of control reaction mixture containing 35 
mg/ml HSA and 20 mM D-glucose in experiment A. The sample was 
incubated in 0.1 M phosphate buffer, pH 7.2 in dark for 2 days before 
analysis. 
 
 
 
 
Figure 3. HPLC-UV elution profile of experimental reaction mixture 
containing 35 mg/ml HSA and 20 mM D-glucose in experiment A. The 
sample was incubated in 0.1 M phosphate buffer, pH 7.2 under UVC 
radiation for 2 days before analysis. 
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Figure 4. HPLC-UV elution profile of control reaction mixture containing 35 
mg/ml HSA and 20 mM D-glucose in experiment A. The sample was 
incubated in 0.1 M phosphate buffer, pH 7.2 in dark for 7 days before 
analysis. 
 
 
 
Figure 5. HPLC-UV elution profile of experimental reaction mixture 
containing 35 mg/ml HSA and 20 mM D-glucose in experiment A. The 
sample has been incubated in 0.1 M phosphate buffer, pH 7.2 under UVC 
radiation for 7 days before analysis. 
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Figure 6. HPLC-UV elution profile of control reaction mixture containing 35 
mg/ml HSA and 20 mM D-glucose in experiment B. HSA was pre-incubated 
in dark for 24 hours before D-glucose was added. The sample was then 
incubated in 0.1 M phosphate buffer, pH 7.2 in dark for 48 hours before 
analysis. 
 
 
 
Figure 7. HPLC-UV elution profile of experimental reaction mixture 
containing 35 mg/ml HSA and 20 mM D-glucose in experiment B. HSA was 
pre-incubated under UVC exposure for 24 hours before D-glucose was 
added. The sample was then incubated in 0.1 M phosphate buffer, pH 7.2 in 
dark for 2 days before analysis. 
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Figure 8. Modified HPLC-UV elution profile of spectrum shown in figure 6. 
Unglycated HSA with a retention time of 14.02 minute was eliminated in the 
spectrum to improve the view of AGE signals. 
 
 
 
Figure 9. Modified HPLC-UV elution profile of spectrum shown in figure 7. 
Unglycated HSA with a retention time of 14.02 minute was eliminated in the 
spectrum to improve the view of AGE signals. 
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Figure 10. Comparison of the production of CML in each reaction mixture in 
experiment A with incubation times of 0, 2 and 7 days. The amount of CML 
was detected with antibodies to glucose-modified HSA using ELISA assay. 
The increase in OD value indicated the accumulation of CML over time. 
Each experiment solution was run in duplicate and the values were 
averaged.  
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Figure 11. Comparison of the production of CML in each reaction mixture in 
experiment B with incubation times of 12, 24 and 48 hours. The amount of 
CML was detected with antibodies to glucose-modified HSA using ELISA 
assay. The increase in OD value indicated the accumulation of CML over 
time. Each experiment solution was run in duplicate and the values were 
averaged.  
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Figure 12. MALDI-TOF profile of reaction mixtures containing 35 mg/ml 
HSA incubated in dark at 37 °C for 7 days. The spectrum peak indicates to 
double charge intact HSA. The maximum peak m/z value was found at 
33000.  
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Figure 13. MALDI-TOF profile of reaction mixtures containing 35 mg/ml 
HSA and 20 mM D-glucose incubated in dark at 37 °C for 2 days 
(experiment A). The spectrum peak indicates to double charged glycated 
HSA. The maximum peak m/z value was found at 33080.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
500
1000
1500
In
te
n
s.
 [a
.u
.]
32600 32800 33000 33200 33400 33600 33800
m /z
162 
 
 
 
Figure 14. MALDI-TOF profile of reaction mixtures containing 35 mg/ml 
HSA and 20 mM D-glucose incubated under UVC radiation at 37 °C for 2 
days (experiment A). The spectrum peak indicates to double charged 
glycated HSA. The maximum peak m/z value was found at 33180.  
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Figure 15. MALDI-TOF profile of reaction mixtures containing 35 mg/ml 
HSA and 20 mM D-glucose incubated in dark at 37 °C for 7 days 
(experiment A). The spectrum peak indicates to double charged glycated 
HSA. The maximum peak m/z value was found at 33280.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
500
1000
1500
In
te
n
s.
 [a
.u
.]
32600 32800 33000 33200 33400 33600 33800
m /z
164 
 
 
 
Figure 16. MALDI-TOF profile of reaction mixtures containing 35 mg/ml 
HSA and 20 mM D-glucose incubated under UVC radiation at 37 °C for 7 
days (experiment A). The spectrum peak indicates to double charged 
glycated HSA. The maximum peak m/z value was found at 33740.  
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Figure 17. MALDI-TOF profile of reaction mixtures containing 35 mg/ml 
HSA and 20 mM D-glucose (experiment B). HSA was pre-incubated in dark 
for 24 hours before D-glucose was added. The sample was then incubated 
in 0.1 M phosphate buffer, pH 7.2 in dark for 2 days before analysis. The 
spectrum peak indicates to double charged glycated HSA. The maximum 
peak m/z value was found at 33100.  
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Figure 18. MALDI-TOF profile of reaction mixtures containing 35 mg/ml 
HSA and 20 mM D-glucose (experiment B). HSA was pre-incubated under 
UVC radiation for 24 hours before D-glucose was added. The sample was 
then incubated in 0.1 M phosphate buffer, pH 7.2 in dark for 2 days before 
analysis. The spectrum peak indicates to double charged glycated HSA. 
The maximum peak m/z value was found at 33290.  
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Table I 
UV readings of reaction mixtures containing 35 mg/ml HSA and 20 mM 
D-glucose incubated in dark or under UVC radiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incubation 
Time 
Experiment A Experiment B 
Dark UV Exposure Dark UV Exposure 
0 d 0.000±0.01 0.000±0.001 0.000±0.002 0.000±0.001 
1 d 0.075±0.003 0.275±0.004 0.091±0.002 0.322±0.004 
2 d 0.287±0.005 0.459±0.002 0.290±0.003 0.507±0.005 
4 d 0.336±0.001 0.713±0.002 0.389±0.003 0.728±0.006 
7 d 0.523±0.006 1.172±0.004 N/A N/A 
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Table II.  
HPLC Peak Areas of unglycated HSA and HSA AGEs generated with or without 
the exposure to UVC radiation in experiment A (7 days) and B (48 hours) 
 Experiment A Experiment B 
dark (Control) 
AGE peak 1 314.7 AGE peak 1  65.5 
AGE peak 2 12.1 AGE peak 2 121.1 
AGE peak 3 72.7 AGE peak 3 50.6 
Unglycated 
HSA 
937.9 
Unglycated 
HSA 
1168.6 
UVC radiation 
(Experimental) 
AGE peak 1 541.6 
AGE peak 1 
and 2 
128.9 
AGE peak 2 15.3 AGE peak 3 125.8 
AGE peak 3 78.4 AGE peak 4 63.0 
Unglycated 
HSA 
715.3 
Unglycated 
HSA 
1051.9 
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Table III. 
Mass Shift of HSA glycated by D-glucose in dark or under the exposure of UVC 
radiation in experiment A and B 
Incubation Condition 
Peak m/z value 
(double charge) 
Glycated BSA shifted 
m/z 
(double charge) 
Approximate number 
of D-glucose 
(m/z=180) adducts 
Experiment A 
HSA Blank 33000 0 0 
HSA + D-glucose in 
dark (2 days) 
33080 80 1 
HSA + D-glucose 
under UVC  
(2 days) 
33180 180 2 
HSA + D-glucose in 
dark (7 days) 
33280 280 3 
HSA + D-glucose 
under UVC  
(7 days) 
33740 740 8 
Experiment B 
HSA Blank 33000 0 0 
HSA + D-glucose in 
dark (48 hours) 
33100 100 1 
HSA + D-glucose 
under UVC  
(48 hours) 
33290 290 3 
 
 
 
 
 
